

AWARD NUMBER: **W81XWH-12-2-0025**

TITLE: **Effect of Antimicrobial Peptide KSL-W on Human Gingival Tissue and *C. albicans* Growth, Transition and Secreted Aspartyl Proteinase (SAPS) 2, 4, 5 and 6 Expressions.**

PRINCIPAL INVESTIGATOR: **Dr. Mahmoud Rouabhia**

CONTRACTING ORGANIZATION: **University of Laval  
Quebec, G1V 046**

REPORT DATE: **July 2016**

TYPE OF REPORT: **Final**

PREPARED FOR: **U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012**

DISTRIBUTION STATEMENT: **Approved for Public Release;**

**Distribution Unlimited**

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

*Form Approved*  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

<b>1. REPORT DATE</b> July 2016		<b>2. REPORT TYPE</b> Final		<b>3. DATES COVERED</b> 1 Apr 2012 - 30 Apr 2016	
<b>4. TITLE AND SUBTITLE</b> Effect of Antimicrobial Peptide KSL-W on Human Gingival Tissue and C. albicans Growth, Transition and Secreted Aspartyl Proteinase (SAPS) 2, 4, 5 and 6 Expressions.				<b>5a. CONTRACT NUMBER</b> W81XWH-12-2-0025	
				<b>5b. GRANT NUMBER</b>	
				<b>5c. PROGRAM ELEMENT NUMBER</b>	
<b>6. AUTHOR(S)</b> Dr. Mahmoud Rouabhia  E-Mail: mahmoud.rouabhia@fmd.ulaval.ca				<b>5d. PROJECT NUMBER</b>	
				<b>5e. TASK NUMBER</b>	
				<b>5f. WORK UNIT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>  University of Laval Quebec, G1V 046				<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b>  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>	
				<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>	
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b>  Approved for Public Release; Distribution Unlimited					
<b>13. SUPPLEMENTARY NOTES</b>					
<b>14. ABSTRACT</b> The antifungal armamentarium for the treatment of systemic fungal infections has increased in recent years. Although very helpful to control/eliminate fungal infections, the available antifungal drugs do have some limitations such as antifungal drug resistance. As an example, azole resistance is an issue in patients with chronic mucocutaneous candidiasis caused by C. albicans in the context of HIV-infected individuals with recurrent oropharyngeal and esophageal candidiasis. A similar trend in vaginal isolates of C. albicans has been seen in women prone to recurrent vaginal candidiasis exposed to long-term fluconazole (Bulik et al., 2009),(Shahid and Sobel, 2009). In the latter scenario – fortunately relatively rare to date – therapeutic options available for oral management of fluconazole-reduced susceptibility C. albicans are few, resulting in the inconvenient use of long-term topical imidazoles. These facts have generated greater interest in the development of new antifungal drugs using various synthetic and naturally occurring antimicrobial molecules. Natural antimicrobial peptides, such as defensins produced by epithelial cells, showed a broad range of antibacterial activity and could play a role in preventing microbial infections(Decanis et al., 2009), (Zaslof, 2002). These antimicrobial peptides generally exhibit selective toxicity for microorganisms and show fewer propensities to induce microbial resistance.					
<b>15. SUBJECT TERMS</b>  Nothing listed					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>	<b>18. NUMBER OF PAGES</b>	<b>19a. NAME OF RESPONSIBLE PERSON</b>
<b>a. REPORT</b>	<b>b. ABSTRACT</b>	<b>c. THIS PAGE</b>			<b>19b. TELEPHONE NUMBER</b> (include area code)
Unclassified	Unclassified	Unclassified	Unclassified	65	USAMRMC

## Table of Contents

	<u>Page</u>
<b>1. Introduction.....</b>	<b>3</b>
<b>2. Keywords.....</b>	<b>3</b>
<b>3. Accomplishments.....</b>	<b>3</b>
<b>4. Impact.....</b>	<b>4</b>
<b>5. Changes/Problems.....</b>	<b>5</b>
<b>6. Products.....</b>	<b>5</b>
<b>7. Participants &amp; Other Collaborating Organizations.....</b>	<b>7</b>
<b>8. Special Reporting Requirements.....</b>	<b>8</b>
<b>9. Appendices.....</b>	<b>8</b>

**Note: This is a duplicative report to the previous ones as no additional research has been done.**

**1-INTRODUCTION:** The antifungal armamentarium for the treatment of systemic fungal infections has increased in recent years. Although very helpful to control/eliminate fungal infections, the available antifungal drugs do have some limitations such as antifungal drug resistance. As an example, azole resistance is an issue in patients with chronic mucocutaneous candidiasis caused by *C. albicans* in the context of HIV-infected individuals with recurrent oropharyngeal and esophageal candidiasis. A similar trend in vaginal isolates of *C. albicans* has been seen in women prone to recurrent vaginal candidiasis exposed to long-term fluconazole (Bulik *et al.*, 2009)(Shahid and Sobel, 2009). In the latter scenario – fortunately relatively rare to date – therapeutic options available for oral management of fluconazole-reduced susceptibility *C. albicans* are few, resulting in the inconvenient use of long-term topical imidazoles. These facts have generated greater interest in the development of new antifungal drugs using various synthetic and naturally occurring antimicrobial molecules. Natural antimicrobial peptides, such as defensins produced by epithelial cells, showed a broad range of antibacterial activity and could play a role in preventing microbial infections(Decanis *et al.*, 2009)(Zaslof, 2002). These antimicrobial peptides generally exhibit selective toxicity for microorganisms and show fewer propensities to induce microbial resistance.

**Scope of the research :** For the development of alternative antifungal treatment, we have synthesized an  $\alpha$ -helical antimicrobial decapeptide, KSL (KKVVFVKVFK), and its analog, KSL-W (KKVVFVWKVFK)(Na *et al.*, 2007), which possess a broad range of antibacterial activity. It killed selected strains of non-oral and oral pathogens, including mutans streptococci. In combination with a surface-active agent, benzalkonium chloride, the peptide significantly reduces *in vitro* biofilm growth(Dixon *et al.*, 2008; Dixon *et al.*, 2009; Leung *et al.*, 2005; Leung *et al.*, 2009).

**2-KEYWORDS:** Fungal treatment, *C. albicans*, Antifungal molecules, fungi resistance, antimicrobial peptides, cationic peptides, chemical peptides, KSL-W.

**3-ACCOMPLISHMENTS:** There was no change as to the original proposal.

**The primary goals of this study were:**

1. To investigate the effect of antimicrobial peptide KSL-W on *C. albicans* growth and biofilm formation under the activation of virulence genes.
2. To investigate the effect of KSL-W on human gingival cell growth and migration/wound healing.

### **Accomplished work**

**Major activities:** We conducted a complete study evaluation the effect of KSL-W on *C. albicans* growth and pathogenesis. **We also conducted a significant study investigating the effect of KSL-W on *in vitro* wound healing.**

**Effect of KSL-W on *C. albicans*:**

- 1) **We specifically** studied the *C. albicans* growth, transition and virulence gene (EFG1, NRG1, EAP1, HWP1, and SAP 2-4-5-6) expression following yeast contact with KSL-W.
- 2) **Results:** We demonstrated that KSL-W markedly reduced *C. albicans* growth at both early and late incubation times. The significant effect of KSL-W on *C. albicans* growth was observed beginning at ten  $\mu\text{g/ml}$  after five h of contact by reducing *C. albicans* transition and at 25  $\mu\text{g/ml}$

by completely inhibiting *C. albicans* transition. Cultured *C. albicans* under biofilm-inducing conditions revealed that both KSL-W and amphotericin B significantly decreased biofilm formation at 2, 4, and six days of culture. KSL-W also disrupted mature *C. albicans* biofilms. The effect of KSL-W on *C. albicans* growth, transition, and biofilm formation/disruption may thus occur through gene modulation, as the expression of various genes involved in *C. albicans* growth, transition and biofilm formation were all down-regulated when *C. albicans* was treated with KSL-W. The effect was greater when *C. albicans* was cultured under hyphae-inducing conditions. These data provide new insight into the efficacy of KSL-W against *C. albicans* and its potential use as an antifungal therapy.

#### **Effect KSL-W on wound healing:**

- 1) **We** specifically investigated the effect of KSL-W on human gingival fibroblasts growth/proliferation, the secretion of metalloproteinases, and their inhibitors, fibroblast migration following wound/scratch, and the KSL-W interaction with fibroblasts to prevent infection by *S. mutans*.
- 2) **Results:** We were able to demonstrate that KSL-W increased the proliferation of gingival fibroblasts through the S and G2/M cell cycle phases. The peptide regulated the secretion of metalloproteinase (MMP)-1 and -2 and their inhibitors TIMP-1 and TIMP-2. Using an *in vitro* wound healing assay, we demonstrated that KSL-W increased the migration of fibroblasts following scratch. Interestingly, the addition of KSL-W peptide to *S. mutans* infected fibroblast culture prevents adverse effect of the bacteria through fibroblast growth and the secretion of IL-8.

All needed information's related to the different protocols we used, and the figures about to the results are included in the published or submitted manuscripts (see appendix 1). As a conclusion, we clearly demonstrated the efficacy of KSL-W on influencing *C. albicans* growth, phase transition and expression of virulence genes. This suggested the usefulness of KSL-W against *C. albicans* pathogenesis. We also demonstrated that KSL-W do not have an adverse effect on human gingival fibroblasts. Furthermore, KSL-W was contributing to increasing wound healing process *in vitro*. However, the use of KSL-W for clinical applications should first be supported by *in vitro* studies using human cells to confirm the non-toxicity of the peptide.

#### **Training:**

1. A student was involved in the project under his Master degree achievement. He was involved in the experimental protocols with *C. albicans*, data collections, and manuscript preparation.
2. The student contributed in presenting the work on antimicrobial peptide KSL-W on the research day of the Faculty of Dentistry, and at the Medical faculty of Laval University.
3. One Postdoc was involved in the objective 2 related to investigating the effect of KSL-W on wound healing. This Postdoc was also involved in writing and submitting the manuscript for publication in a peer review scientific journal.
4. The Postdoc contributed presenting the data related to the efficacy of KSL-W on wound healing at the 10<sup>th</sup> research day of the Faculty of Dentistry of Laval University.

#### **Results dissemination:**

The results were disseminated through publications and presentations.

**4-IMPACT:** The major accomplishment is the understanding the mechanism(s) by which antimicrobial peptide KSL-W in reducing *C. albicans* pathogenesis *in vitro*. The other important achievement is the demonstration for the first time that KSL-W can promote wound healing. This demonstrated by increasing primary human gingival fibroblast growth, migration and the secretion of IL-8 mediators. **It is important to conceive further studies to support such innovative results related to the implication of KSL-W in wound healing. This can include gingival human epithelial cells as monolayers, but also a three dimensional engineered human oral mucosa to mimic the real wound healing process in human.**

**The impact on the development of the principal discipline(s) of the project**

We clearly demonstrated that KSL-W was effective in reducing *C. albicans* growth, transition through the down-regulation of certain important genes involved in biofilm formation. This consolidates the previous studies on inhibition of bacterial growth and suggests the potential use of KSL-W against microbial infections in human. We also demonstrated for the first time the implication of KSL-W in promoting wound healing.

**The impact on other disciplines**

*Nothing to Report.*

**The impact on technology transfer**

*Nothing to Report.*

**The impact on society beyond science and technology**

Our studies demonstrated the potential use of KSL-W to:

1. Control bacterial and fungal infections in human and probably in animals.
2. To promote wound healing in human, as the peptide increases *in vitro* wound healing parameters of human gingival fibroblasts.
3. Eventually the data generated through these studies may suggest the use of KSL-W to control infection and minimize the emergence of microbial resistance. Such improvement may be of great economic improvement in reducing infection and promoting person health. This will allow more active work, thus economic improvement. It may also be very important for the design of new antimicrobial molecules, thus giving good treatment alternative, and creating more jobs.

**5-CHANGES/PROBLEMS:**

Nothing to report.

**Changes in approach and reasons for change**

Nothing to report.

**Changes that had a significant impact on expenditures**

Nothing to report.

**Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents**

*Nothing to Report.*

**Significant changes in use or care of human subjects**

*Nothing to Report.*

**Significant changes in use or care of vertebrate animals.**

*Nothing to Report.*

**Significant changes in use of biohazards and/or select agents.**

*Nothing to Report.*

**6-PRODUCTS:**

*Nothing to Report.*

**Publications, conference papers, and presentations**

**Journal publications.**

Theberge S, Semlali A, Alamri A, Leung KP, Rouabhia M. C. albicans growth, transition, biofilm formation, and gene expression modulation by antimicrobial decapeptide KSL-W. BMC Microbiol. 2013 Nov 7;13:246. doi: 10.1186/1471-2180-13-246.

**Status of publication:** Published

**Acknowledgement of federal support:** Yes

Hyun-Jin Park, Mabrouka Salem, Abdelhabib Semlali, Kai P Leung, Mahmoud Rouabhia: Antimicrobial peptide KSL-W promotes gingival fibroblast growth, migration, and defense against *Streptococcus mutans* infection. J Appli Micro. (under review), 2016.

**Status of publication:** Under review

**Acknowledgement of federal support:** Yes

**Abstracts:**

1. Theberge Simon, Jacques Éric and Leung Kai P and Rouabhia Mahmoud. Un nouveau peptide antimicrobien contrôle la virulence de Candida en réduisant sa viabilité via un processus d'apoptose et de nécrose. Journée de la recherche GREB/FMD, le 10 mai, 2013

**Status of publication:** Published in the event proceeding

**Presentation:** Oral

**Acknowledgement of federal support:** Yes

2. Théberge Simon, Jacques Éric, Leung Kai P and **Rouabhia Mahmoud**. Un nouveau peptide antimicrobien contrôle la virulence de Candida en réduisant sa viabilité via un processus d'apoptose et de nécrose. Journée de la recherche faculté de médecine – 30 mai 2013, Université Laval. Québec.

**Status of publication:** Published in the event proceeding

**Presentation:** Oral

**Acknowledgement of federal support:** Yes

3. Théberge Simon, Semlali Abdelhabib, Alamri Abdullah, Leung P. Kai, and **Rouabhia Mahmoud**. Le KSL-W réduit la croissance de Candida albicans et la formation de biofilm en diminuant l'expression de plusieurs gènes de virulence. 81<sup>e</sup> Congrès de l'Acfas, du 6 au 10 mai 2013, Université Laval, Québec, Canada.

**Status of publication:** Published in the event proceeding

**Presentation:** Oral

**Acknowledgement of federal support:** Yes

4. Hyun-Jin Park, Mabrouka Salem, Abdelhabib Semlali, Kai P Leung, Mahmoud Rouabhia. Investigating the effect of an antimicrobial peptide (KSL-W) on gingival fibroblast growth, migration, and defense against microbial infection. 10<sup>th</sup> research day, Dental faculty, Laval University, may 5<sup>th</sup>, 2016.

**Status of publication:** Published in the event proceeding

**Presentation:** Oral

**Acknowledgement of federal support:** Yes

#### **Other publications, conference papers, and presentations.**

*None*

#### **Website(s) or other Internet site(s)**

*None*

#### **Technologies or techniques**

*None*

#### **Inventions, patent applications, and/or licenses**

*None*

#### **Other Products**

*None*

### **7-PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS**

#### **What individuals have worked on the project?**

See below Tables.



<b>Name:</b>	Simon Theberge
<b>Project Role:</b>	Graduate Student
<b>Researcher Identifier (e.g. ORCID ID):</b>	University Laval Student
<b>Nearest person month worked:</b>	20 h a week
<b>Contribution to Project:</b>	M. Theberge has performed a large part of the experimental protocol related to the evaluation of the effect of KSL-W on <i>C. albicans</i> .
<b>Funding Support:</b>	

<b>Name:</b>	M. Abdelhabib Semlali
<b>Project Role:</b>	Post-Doc, then collaborator, visiting professor
<b>Researcher Identifier (e.g. ORCID ID):</b>	
<b>Nearest person month worked:</b>	Five h a week
<b>Contribution to Project:</b>	M. Semlali has supervised the grad student.
<b>Funding Support:</b>	Laval University Foundation

<b>Name:</b>	Abdullah Alamri
<b>Project Role:</b>	Graduate Student
<b>Researcher Identifier (e.g. ORCID ID):</b>	University Laval student
<b>Nearest person month worked:</b>	5
<b>Contribution to Project:</b>	M. Alamri contributed, with the grad student M. Teberge to perform the genes expression protocols and data collection and analyses.
<b>Funding Support:</b>	

<b>Name:</b>	Mabrouka Salem
--------------	----------------

<b>Project Role:</b>	Technical support
<b>Researcher Identifier (e.g. ORCID ID):</b>	University Laval student
<b>Nearest person month worked:</b>	5
<b>Contribution to Project:</b>	She was involved in the cell preparation to perform the wound healing experiments.
<b>Funding Support:</b>	

<b>Name:</b>	Hyun Jin Park
<b>Project Role:</b>	Postdoc student
<b>Researcher Identifier (e.g. ORCID ID):</b>	University Laval student
<b>Nearest person month worked:</b>	15
<b>Contribution to Project:</b>	She was involved in performing most of the study related to the wound healing with KSL-W
<b>Funding Support:</b>	

<b>Name:</b>	Leung KP
<b>Project Role:</b>	Collaborator
<b>Researcher Identifier (e.g. ORCID ID):</b>	
<b>Nearest person month worked:</b>	5
<b>Contribution to Project:</b>	K. Leung has contributed the study design and manuscript revision.
<b>Funding Support:</b>	

**Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?**

*Nothing to Report.*

**The Organizations involved as partners**

**The University Laval as an involved organization.**

At the dental Faculty of Laval University, I was able to use different equipment to perform the study and get publishable results. Without such in-kind supports, the study would be very

difficult/impossible to realize. The equipment's at the research center of the Dental Faculty at Laval University were obtained thanks to the financial supports of University Laval and different funds that Dr Rouabhia obtained previously from different funding agencies. These include the CIHR, NSERC, FRSQ, the Fonds Émile-Beaulieu at the dental Faculty of Laval University, and so.

## **8-SPECIAL REPORTING REQUIREMENTS**

*Nothing to Report.*

## **9-APPENDICES:**

Appendix A: Published and submitted manuscripts

Appendix B: Presented abstracts (1, 2, 3 and 4).

RESEARCH ARTICLE

Open Access

# *C. albicans* growth, transition, biofilm formation, and gene expression modulation by antimicrobial decapeptide KSL-W

Simon Theberge<sup>1</sup>, Abdelhabib Semlali<sup>1,2</sup>, Abdullah Alamri<sup>1</sup>, Kai P Leung<sup>3</sup> and Mahmoud Rouabhia<sup>1\*</sup>

## Abstract

**Background:** Antimicrobial peptides have been the focus of much research over the last decade because of their effectiveness and broad-spectrum activity against microbial pathogens. These peptides also participate in inflammation and the innate host defense system by modulating the immune function that promotes immune cell adhesion and migration as well as the respiratory burst, which makes them even more attractive as therapeutic agents. This has led to the synthesis of various antimicrobial peptides, including KSL-W (KKWFWWKF-NH<sub>2</sub>), for potential clinical use. Because this peptide displays antimicrobial activity against bacteria, we sought to determine its antifungal effect on *C. albicans*. Growth, hyphal form, biofilm formation, and degradation were thus examined along with EFG1, NRG1, EAP1, HWP1, and SAP 2-4-5-6 gene expression by quantitative RT-PCR.

**Results:** This study demonstrates that KSL-W markedly reduced *C. albicans* growth at both early and late incubation times. The significant effect of KSL-W on *C. albicans* growth was observed beginning at 10 µg/ml after 5 h of contact by reducing *C. albicans* transition and at 25 µg/ml by completely inhibiting *C. albicans* transition. Cultured *C. albicans* under biofilm-inducing conditions revealed that both KSL-W and amphotericin B significantly decreased biofilm formation at 2, 4, and 6 days of culture. KSL-W also disrupted mature *C. albicans* biofilms. The effect of KSL-W on *C. albicans* growth, transition, and biofilm formation/disruption may thus occur through gene modulation, as the expression of various genes involved in *C. albicans* growth, transition and biofilm formation were all downregulated when *C. albicans* was treated with KSL-W. The effect was greater when *C. albicans* was cultured under hyphae-inducing conditions.

**Conclusions:** These data provide new insight into the efficacy of KSL-W against *C. albicans* and its potential use as an antifungal therapy.

**Keywords:** Antimicrobial peptide, KSL-W, *C. albicans*, Growth, Hyphae, Gene, EFG1, NRG1, HWP1, SAPs

## Background

The innate defense system plays a key role in protecting the host against microorganism-fueled infections such as candidiasis caused by *Candida albicans*. *C. albicans* colonizes several body sites, including the oral cavity; however, as a commensal organism, it causes no apparent damage or inflammation in the surrounding tissue [1,2]. *C. albicans* is a polymorphic organism that adheres to different surfaces in the body and can grow as yeast, pseudohyphae, and hyphae [3], usually in the form of biofilm. *C. albicans* transition, biofilm formation, and

pathogenesis are under the control of various genes. The *HWP1* gene encodes the hyphal cell wall protein, which is a hyphal-specific adhesin that is essential to biofilm formation [4]. The involvement of *HWP1* in *C. albicans* adhesion is supported by the *EAP1* gene which encodes a glucan-crosslinked cell wall protein (adhesin Eap1p). Together, these components mediate *C. albicans* adhesion to various surfaces, such as epithelial cells and polystyrene [5]. Like many other genes, *HWP1* and *EAP1* are downstream effectors of EFG1 and NRG1 as transcription factors [6,7]. *EFG1* mutant strain has been shown to exhibit defects in growth, biofilm formation, and virulence [8], while NRG1 represses filamentous growth [3]. This occurs through the DNA binding protein Nrg1p in conjunction with the global transcriptional repressor

\* Correspondence: mahmoud.rouabhia@fmd.ulaval.ca

<sup>1</sup>Oral Ecology Research Group, Faculty of Dentistry, Laval University, 2420, rue de la Terrasse, Quebec G1V 0A6, QC, Canada

Full list of author information is available at the end of the article

Tup1p to suppress hyphal formation. Elevated NRG1 expression represses the expression of a number of hypha-specific genes, although NRG1 downregulation is associated with *C. albicans* filaments [3].

*C. albicans* virulence is also mediated by proteolytic enzymes, including secreted aspartyl proteinases (SAPs) [9,10]. The contribution of SAPs in *C. albicans* adherence, tissue damage, and evasion of host immune responses has been reported [9]. SAP2 is crucial to *C. albicans* growth in protein-containing media [11]. SAP1 and SAP3 are expressed during phenotypic switching [12,13], while SAP4, SAP5, and SAP6 are expressed upon hyphal formation [14], and SAPs 1-6 and 9-10 are involved in the adhesion mechanism to host cells [15].

To control *C. albicans* pathogenesis, the host innate immunity uses small molecules such as proteins and peptides that display a broad antimicrobial spectrum. The number of identified potentially antimicrobial peptides is significant and continues to increase [16]. Antimicrobial peptides often possess common attributes, such as small size, an overall positive charge, and amphipathicity [17,18]; however, they also fall into a number of distinctively diverse groups, including  $\alpha$ -helical peptides,  $\beta$ -sheet peptides, peptides with mixed  $\alpha$ -helical and  $\beta$ -sheet structures, extended peptides, and peptides enriched in specific amino acids [16].

In humans, epithelial cells and neutrophils are the most important cells producing antimicrobial peptides [19,20]. These peptides are most often antibacterial, although antifungal activity has also been reported [16,21]. The major peptide groups known to date are the histatins, cathelicidins, defensins, and lactoferricins [22]. The antimicrobial activity of these peptides has been reported by different *in vitro* and *in vivo* studies [19,20,22]. Their complex role as well as their contribution to host defenses may be related to the functional interrelationship between innate and adaptive immunity [23,24].

The interest in antimicrobial peptides lies in the possible resistance of microorganisms to conventional antimicrobial strategies used against microbial pathogens in both agriculture and medicine [25,26]. Natural antimicrobial peptides are necessary in the control of microbial infections. For example, the use of AMPs provided protection against such microbial pathogens as fungal pathogens, with no reported effect on the host [27,28]. Based on these promising data, a number of synthetic AMPs have been designed to overcome microbial infections [29]. In the pursuit of a novel alternative antifungal treatment, we developed a synthetic  $\alpha$ -helical antimicrobial decapeptide, KSL (KKVVFVKVFKF), and its analogue KSL-W (KKVVFVVKVFKF) [30].

The efficacy of KSL on a wide range of microorganisms has been established [31-33], as well as its ability to disrupt oral biofilm growth [34]. KSL-W, a recently

synthesized KSL analogue, was shown to display improved stability in simulated oral and gastric conditions with *in vitro* preserved antimicrobial activity [30]. Furthermore, combined with sub-inhibitory concentrations of benzalkonium chloride, a known cationic surface-active agent [35], KSL was shown to significantly promote bacterial biofilm susceptibility. We also recently demonstrated that KSL-W had a selective effect on *C. albicans* growth, while exhibiting no toxic effect on epithelial cells [36].


As this KSL-W analogue displays a wide range of microbicidal activities, effectively kills bacteria, controls biofilm formation, and destroys intact biofilms, we hypothesized that KSL-W may also possess antifungal potential. Our goal was thus to investigate the ability of KSL-W to inhibit *C. albicans* growth and transition from blastospore to hyphal form. The action of KSL-W on biofilm formation/disruption was also assessed. Finally, we examined the effect of KSL-W on various *C. albicans* genes involved in its growth, transition, and virulence.

## Results

### Antimicrobial peptide KSL-W reduced *C. albicans* growth and transition from blastospore to hyphal form

*C. albicans* cultures were incubated with KSL-W for 5, 10, and 15 h to determine whether this antimicrobial peptide had any adverse effect on *C. albicans* growth. As shown in Figure 1, KSL-W significantly reduced *C. albicans* proliferation. After 5 h of contact with KSL-W, the growth inhibition of *C. albicans* was between 30 and 80%, depending on the concentration of KSL-W used (Figure 1A). After 10 h of contact with KSL-W, growth inhibition was significant, beginning at 25  $\mu$ g/ml (Figure 1B). At later culture periods, *C. albicans* growth continued to be significantly affected by the presence of KSL-W (Figure 1C). Indeed, with 25  $\mu$ g/ml of KSL-W, *C. albicans* growth was almost half that in the controls (non-treated *C. albicans* cultures), and with 100  $\mu$ g/ml of KSL-W, *C. albicans* growth was reduced by almost 60%. It is interesting to note that KSL-W in as low as 25  $\mu$ g/ml was effective at both the early and late culture periods.

As KSL-W contributed to *C. albicans* growth inhibition, we hypothesized that it would also downregulate *C. albicans* transition from yeast form to hyphal phenotype. Yeast cultures supplemented with 10% FBS and the KSL-W peptide were maintained for various incubation periods. As shown in Figure 2, germ tube formation was inhibited as early as 4 h following exposure to the peptide, compared to that in the cultures incubated in the absence of KSL-W. Of interest is the elevated number of *C. albicans* hyphal forms in the negative control culture (no KSL-W or amphotericin B) compared to the low number in the presence of KSL-W. The effect of this



antimicrobial peptide on *C. albicans* transition was also dose-dependent: at 1 µg/ml, a significant number of hyphal forms remained, and at only 5 µg/ml of KSL-W, *C. albicans* transition was completely inhibited (Figure 2). Semi-quantitative analyses using inverted microscope observations to estimate the hyphal forms confirmed the inhibited *C. albicans* transition when treated with KSL-W (Table 1). The density of the hyphae was reduced as early as 4 h of contact with 5 µg/ml of KSL-W. This effect was further supported when *C. albicans* was placed in contact with KSL-W for 8 h (Table 1), thus confirming that KSL-W downregulated *C. albicans* growth and transition.

### KSL-W reduced *C. albicans* biofilm formation


As KSL-W contributed to reducing *C. albicans* growth and transition, we sought to determine whether it also displayed inhibitory activity against *C. albicans* biofilm formation. Using a biofilm-promoting scaffold, SEM analyses, and an XTT assay, we were able to demonstrate the inhibitory effect of KSL-W on biofilm formation (Figure 3). SEM analyses revealed a significant density of *C. albicans* in the untreated culture, compared to a lower density in the scaffold in the presence of KSL-W (1 and 25 µg/ml) after 4 days of culture. The decreases obtained with the KSL-W, particularly at 25 µg/ml (Figure 3), were comparable to that obtained with amphotericin B at 10 µg/ml. To confirm these observations, we performed quantitative analyses using the XTT assay. Figure 4A shows that after 2 days of culture, KSL-W was able to inhibit biofilm formation. This inhibitory effect was observed beginning at 25 µg/ml of KSL-W. At concentrations of 50, 75, and 100 µg/ml of KSL-W, the inhibition of *C. albicans* biofilm formation was comparable to that caused by amphotericin B at 10 µg/ml. Similar results were obtained after 4 days (Figure 4B) and 6 days (Figure 4C) of culture for biofilm formation with a persistent inhibitory effect of KSL-W on *C. albicans* biofilm formation.

### KSL-W disrupted mature *C. albicans* biofilms

After 6 days of incubation in glucose-rich Sabouraud medium, scaffolds seeded with *C. albicans* strain SC5314 produced mature biofilms displaying highly dense populations of *Candida* cells (Figure 5). Significant reductions and disruptions of the pre-formed *Candida* biofilms were observed when the reference antifungal agent (amphotericin B, 10 µg/ml) was added to the mature biofilms upon further incubation up to 6 days. Similarly, antimicrobial peptide KSL-W at 75 and 100 µg/ml also reduced *C. albicans* density in the biofilms. The observed reduction was noticed with KSL-W concentrations ranging from 25 to 100 µg/ml. Indeed, when quantitatively investigated by XTT reduction assay, the KSL-W-treated biofilms rendered a significantly lower number of cells, as reflected by the lower absorbance readings, than did the untreated control. This effect was observed after 2, 4, and 6 days of treatment with amphotericin B. Furthermore, the effect of KSL-W on the mature *C. albicans* biofilm was comparable to that obtained with amphotericin B (Figure 6).

### KSL-W modulated the expression of various *C. albicans* genes

Based on the data showing that KSL-W reduced *C. albicans* proliferation, transition, and biofilm formation, we sought to determine the involvement, if any, of gene regulation. For this purpose, we first investigated the



**Figure 2** KSL-W inhibited *C. albicans* yeast-to-hyphae transition. *C. albicans* was cultured in Sabouraud medium containing 10% fetal bovine serum with or without KSL-W at various concentrations and was maintained for 4 and 8 h at 37°C. After each time point, the cultures were observed under an inverted microscope and photographed. Representative photos of the morphological changes after 4 h of culture are presented.


**Table 1** Estimation of hyphae forms in the *C. albicans* culture

Active molecules	Concentration (µg/mL)	Transition at 4 h	Transition at 8 h
Negative control	0	++	++
KSL-W	1	++	++
	5	-	-
	10	-	-
	15	-	-
	25	-	-
	100	-	-
Amphotericin B	1	-	-

This Table depicts the presence of hyphae following 4 and 8 h treatments of *C. albicans* with and without KSL-W or amphotericin B. (-) refers to the absence hyphae form, and (++) refers to the presence high number of hyphae forms. These data were estimated after evaluation over 20 fields from each culture condition, by two independent and blinded examiners.

effect of KSL-W on the activation/repression of various *C. albicans* genes when cultured under normal non-hyphae-inducing conditions. The data in Table 2 indicate that the HWP1 gene was significantly downregulated following exposure of the *C. albicans* to KSL-W for 6 h. This downregulation was comparable to that observed in the amphotericin B treatment. Similarly, SAPs 2, 4, 5, and 6 were significantly downregulated by KSL-W treatment after 6 h (Table 2). This effect was observed with both low and high concentrations of KSL-W. Furthermore, the EAP1 gene, which encodes a glycosylphosphatidylinositol-anchored, glucan-crosslinked cell wall protein in both adhesion and biofilm formation *in vitro* and *in vivo*, was also affected by the KSL-W treatment. Moreover, the expression of this gene was downregulated by KSL-W, yet was upregulated (up to 5-fold) by amphotericin B.

Two other genes involved in regulating *C. albicans* morphogenesis, namely, *EFG1* and *NRG1*, are known to



**Figure 3** Scanning electron microscope analyses of the biofilm formation. *C. albicans* was cultured in Sabouraud medium with or without KSL-W at various concentrations for 4 days in a porous 3D collagen scaffold. Cultures in the presence of amphotericin B (10 µg/ml) were used as the positive controls. Following incubation, the samples were prepared as described in the Methods section and were observed under a scanning electron microscope. Negative control refers to the non-seeded scaffolds.


be hyphae repressors. In our study, amphotericin B increased both *EFG1* and *NRG1* mRNA expression, with twice as much expression for *NRG1* than for *EFG1* (Table 3), while KSL-W induced a less significant increase of *EFG1* and *NRG1* mRNA expression. Of interest is that a low KSL-W concentration (25 µg/ml) induced greater gene expression (Table 3).

In a second set of experiments, *C. albicans* was cultured under hyphae-inducing conditions (fetal calf serum-enriched medium with incubation at 37°C) in the presence or not of KSL-W, after which time gene expression/repression was investigated. The data in Table 4 reveal that similar to the results obtained with amphotericin-B, the *HWPI* gene was significantly ( $p < 0.0001$ ) downregulated when *C. albicans* was exposed to

KSL-W for 3 h, confirming the results obtained under non-hyphae growth conditions.

*SAP* genes were also modulated by KSL-W treatment. Table 4 shows that after 3 h of exposure, *SAPs* 2, 4, 5, and 6 were significantly ( $p < 0.05$ ) downregulated by the KSL-W treatment. In contrast, with amphotericin-B, a significant ( $p < 0.05$ ) increase of *SAPs* 2, 4, and 6 and a decrease of *SAP5* was observed. It is interesting to note the opposite modulatory effects of KSL-W and amphotericin-B on *SAP* gene expression. After 6 h of treatment with KSL-W, a significant decrease of each tested *SAP* gene was observed in the exposed *C. albicans*, whereas after treatment with amphotericin-B, these same *SAP* genes increased, thus confirming the antagonistic behavior of KSL-W and amphotericin-B on *SAP* gene expression.





*C. albicans* *EAP1* gene expression was unchanged after 3 h with KSL-W, but significantly ( $p < 0.001$ ) decreased after 6 h, while the expression of this gene was upregulated (close to six folds) by amphotericin B (Tables 4 and 5). Amphotericin B increased *NRG1* mRNA expression almost


threefold, with no significant effect on the *EFG1* gene, yet significantly decreased *HWP1* gene expression. On the other hand, after 3 h (Table 4) and 6 h (Table 5) of incubation, KSL-W downregulated *EFG1*, *NRG1*, and *HWP1* mRNA expression. Of interest is that except for similar downregulatory effects on *HWP1* gene expression, KSL-W and amphotericin-B produced once again opposite results regarding *EFG1* and *NRG1* gene expression.

## Discussion and conclusions

We demonstrated that KSL-W was effective in inhibiting *C. albicans* growth at short and long culture periods. Although growth inhibition obtained with KSL-W was less than that obtained with amphotericin B, the effects of KSL-W nevertheless remain significant ( $p < 0.01$ ). The growth inhibition effects of KSL-W are in accordance with previously reported findings [37] showing a downregulation of *C. albicans* activity induced by a bacteriocin-like peptide isolated from *Lactobacillus pentosus*. Furthermore, our results support other findings [38] reporting the effectiveness of KSL-W in disrupting *P. gingivalis*-induced hemagglutination and its synergistic interaction with host AMPs engaged in innate defense. The results strongly suggest that KSL-W is also effective against fungal growth and may be suitable for use to control *C. albicans* infections. Further studies on the possible synergistic effect of amphotericin B and KSL-W against *C. albicans* growth may provide insight.

*C. albicans* pathogenesis can also take place through the transition from blastospore to hyphal form [39,40]. Our results indeed show that KSL-W completely inhibited *C. albicans* transition with a concentration as low as 5 µg/ml. These data are consistent with those of other studies with naturally occurring antimicrobial peptides (e.g.,  $\beta$ -defensins) which were effective in blocking the morphological shift of *Candida* from yeast to hyphae [41,42]. Thus KSL-W may possibly contribute to the control of *C. albicans* infection by reducing cell growth and yeast-hyphae transition. The effect of KSL-W on *C. albicans* growth can occur either through cytolysis or cell membrane disruption, resulting in cell death similar to what has been demonstrated with histatin-5 [43,44]. Indeed, it was shown that histatin-5 induces the selective leakage of intracellular ions and ATP from yeast cells. This is caused by the translocation of histatin-5 into the intracellular compartment and accumulates to a critical concentration [45]. Further studies are thus warranted to shed light on the fungicidal mechanism of KSL-W.

*C. albicans* growth and transition from blastospore to hyphal form are particularly important for biofilm formation and *C. albicans* virulence because a strain that is genetically manipulated to grow exclusively in the yeast form is greatly hindered in generating biofilms. In addition, a variety of *C. albicans* mutants known to be




**Figure 5 Biofilm ultrastructure following KSL-W treatment.** *C. albicans* was cultured in Sabouraud medium without KSL-W for 6 days to promote biofilm formation and maturation. The resulting biofilms were then treated or not with KSL-W or amphotericin B for 6 days, with medium and peptide refreshing every 2 days. Following incubation, the samples were prepared as described in the Methods section and observed under a scanning electron microscope.

unable to form hyphae also show biofilm defects [46,47]. As KSL-W significantly reduced *C. albicans* growth and inhibited its transition from yeast to hyphae, this suggests that KSL-W may inhibit *C. albicans* biofilm formation. Our findings indicate that KSL-W was indeed able to reduce biofilm formation and that its effect was comparable to that obtained with amphotericin B, a well-known antifungal molecule. Also of interest is that a significant inhibition of *C. albicans* biofilm formation was obtained at a concentration of as low as 25 µg/ml of KSL-W antimicrobial peptide. These useful data are comparable to those of other studies showing the positive action of synthetic peptide in controlling and preventing microbial biofilm formation [48]. Thus, with its significant impact in reducing *C. albicans* biofilm formation, KSL-W may show potential for several novel applications in the clinical setting. Further investigations will elucidate this effect.

Biofilm formation can be controlled with anti-biofilm molecules prior to its development, although this is not actually the case in clinical applications, as antifungal and microbial molecules cannot be used on a daily basis to prevent biofilm formation. An effective molecule should ideally be able to prevent biofilm formation, but more importantly to disrupt biofilms that are already formed. We therefore questioned whether KSL-W was capable of disrupting mature *C. albicans* biofilm.

We proceeded to examine the impact of KSL-W on mature biofilm formation and demonstrated a significant disruption of these biofilms following contact with KSL-W, thus suggesting the possible use of this antimicrobial peptide to reduce/eliminate mature biofilms. Further studies should confirm such observations and demonstrate how KSL-W reduces or disrupts *C. albicans* biofilms.

Once it reaches the cell, KSL-W can potentially act on the cytoplasmic membrane as well as on intracellular targets [49-51]. The action of KSL-W against *C. albicans* may operate through the modulated expression of certain *C. albicans* genes that control growth [52], transition [53], and biofilm formation [54]. We therefore examined the effect of KSL-W on a number of genes either directly or indirectly involved in phase transition and biofilm formation. *EFG1* and *NRG1* expression was assessed under hyphae/non-hyphae-inducing conditions. Our results show that KSL-W increased *NRG1* mRNA expression twofold under non-hyphae-inducing conditions; however, under hyphae-inducing conditions, KSL-W significantly reduced *NRG1* gene expression. These findings contrast with other reports that an increased *NRG1* expression contributes to repressing various hypha-specific genes [55,56]. This confirms that the effect of KSL-W in controlling *C. albicans* virulence does not take place through *NRG1*. KSL-W was also able to



decrease EFG1 mRNA expression, when *C. albicans* was maintained under hyphae-inducing conditions.

EFG1p has been found to be a central regulator of *C. albicans*, as it is required for the development of a true hyphal growth form, and EFG1 is considered to be essential in the interactions between *C. albicans* and human host cells [7,8]. The downregulation of this gene by KSL-W points to the singular role of this antifungal peptide. Thus the effect of KSL-W on *C. albicans* transition can be manifested through a repression of certain genes, such as *EFG1* and *NRG1*.

KSL-W has a significant inhibitory effect on EAP1 mRNA expression. As a member of the GPI-CWP family [5,57], deleting EAP1 can reduce the adhesion of *C. albicans* to different surfaces. This suggests that treatment with KSL-W may reduce EAP1 expression, which in turn may contribute to reducing *C. albicans* adhesion and ultimately, biofilm formation and pathogenesis. KSL-W was also shown to reduce HWP1 mRNA expression, particularly when *C. albicans* was cultured under hyphae-inducing conditions.

HWP1 is a downstream component of the cAMP-dependent PKA pathway and is positively regulated by EFG1 [58]. The transcript level of HWP1 decreased with the KSL-W treatment at low and high concentrations. These data suggest that KSL-W indeed impacts the activity of the cAMP–EFG1 pathway and leads to an alteration of *C. albicans* growth and morphogenesis. Further studies are therefore required to investigate the invasion/virulence of KSL-W-treated *C. albicans*.

It is well known that *Candida* pathogenesis can be established by virtue of *Candida* growth and yeast-to-hyphae morphogenesis. Specific *SAP* genes were found to be preferentially expressed by *Candida* hyphal forms [10,15,59]. Because KSL-W downregulated *C. albicans* growth and transition, this may have occurred through a modulation of the *SAP* genes. Our findings confirm that KSL-W is capable of decreasing *SAP2*, *SAP4*, *SAP5*, and *SAP6* mRNA expression in *C. albicans* which may lead to reducing *C. albicans* virulence [60–62].

Our study thus establishes, for the first time, a clear link between an antimicrobial peptide (KSL-W), hyphae

**Table 2 Gene expression (6 h) under non-hyphae inducing culture conditions**

Gene	Untreated <i>C. albicans</i>	Amphotericin B		KSL-W 25 µg/ml		KSL-W 100 µg/ml	
	Fold change <sup>1</sup>	Fold change <sup>1</sup>	p-value <sup>2</sup>	Fold change <sup>1</sup>	p-value <sup>2</sup>	Fold change <sup>1</sup>	p-value <sup>2</sup>
<i>SAP2</i>	0.99	0.57	0.001	0.24	<0.001	0.11	<0.001
<i>SAP4</i>	0.96	0.19	<0.001	0.29	<0.001	0.14	<0.001
<i>SAP5</i>	1.00	0.08	<0.001	0.16	<0.001	0.06	<0.001
<i>SAP6</i>	1.00	0.05	<0.001	0.14	<0.001	0.04	<0.001
<i>EAP1</i>	1.00	4.91	0.028	0.4	<0.001	0.29	<0.001
<i>HWP1</i>	1.00	0.01	<0.001	0.6	0.032	0.02	<0.001

<sup>1</sup>Fold change was calculated by PCR product of the gene of interest/the PCR product of ACT1 (the house keeping gene), and normalized to the negative control of untreated *C. albicans* where the expression was considered equal to 1.

<sup>2</sup>P-values were obtained after comparison of test to negative control (untreated *C. albicans*).

**Table 3 Gene expression (3 h) under non-hyphae inducing culture conditions**

Gene	Untreated <i>C. albicans</i>	Amphotericin B		KSL-W 25 µg/ml		KSL-W 100 µg/ml	
	Fold change <sup>1</sup>	Fold change <sup>1</sup>	p-value <sup>2</sup>	Fold change <sup>1</sup>	p-value <sup>2</sup>	Fold change <sup>1</sup>	p-value <sup>2</sup>
<i>EFG1</i>	1.00	5.71	<0.001	2.76	<0.001	1.98	0.073
<i>NRG1</i>	1.00	10.99	<0.001	1.77	<0.001	1.4	0.086

<sup>1</sup>Fold change was calculated by PCR product of the gene of interest/the PCR product of ACT1 (the house keeping gene), and normalized to the negative control of untreated *C. albicans* where the expression was considered equal to 1.

<sup>2</sup>P-values were obtained after comparison of test to negative control (untreated *C. albicans*).

morphogenesis, and hyphae-modulating SAPs 2, 4, 5, and 6. However, the precise interactions between these SAPs and KSL-W during *C. albicans* pathogenesis remain unclear. Additional studies should focus on identifying the role of SAP subfamilies involved in *Candida* invasion as well as the role of KSL-W in controlling *Candida* virulence/pathogenesis in conjunction with host defenses. In conclusion, this study is the first to demonstrate that synthetic antimicrobial peptide KSL-W downregulates *C. albicans* growth and transition, resulting in a decrease in biofilm formation and a disruption of mature biofilm. Also of interest is that these effects may occur through the modulation of *C. albicans* genes *EFG1*, *NRG1*, *EAP1*, *HWP1*, and *SAPs*. Overall results clearly suggest the potential of KSL-W as an antifungal molecule.

## Methods

### *C. albicans*

*C. albicans* strain ATCC-SC5314 was cultured for 24 h on Sabouraud dextrose agar plates (Becton Dickinson, Oakville, ON, Canada) at 30°C. For the *C. albicans* suspensions, one colony was used to inoculate 10 ml of Sabouraud liquid medium supplemented with 0.1% glucose at pH 5.6. The cultures were grown overnight in a shaking water bath for 18 h at 30°C. The yeast cells were then collected, washed with phosphate-buffered saline (PBS), counted with a haemocytometer, and adjusted to 10<sup>7</sup>/ml prior to use.

### Antimicrobial peptides

KSL-W (KKVVFVWVKFK-NH<sub>2</sub>) was synthesized by standard solid-phase procedures [63] with 9-fluorenylmethoxycarbonyl (Fmoc) chemistry in an automatic peptide synthesizer (model 90, Advanced ChemTech, Louisville, KY, USA). The synthetic peptides were then purified by reverse-phase HPLC (series 1100, Hewlett Packard) by means of a Vydac C18 column. Peptide purity was confirmed by MALDI-TOF (matrix-assisted laser desorption/ionization-time of flight) MS (AnaSpec Fremont, CA, USA). The final product was stored in lyophilized format -20°C until use. KSL-W solution was prepared, filtered (0.22 µm pore size), and used for the experiments. Amphotericin B (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in distilled water to obtain a 250 µg/ml concentration which was also filtered, with the sterile solution stored at -80°C until use.

### Effect of KSL-W on *C. albicans* proliferation

Proliferation was investigated by placing 10<sup>4</sup> *C. albicans* in 200 µL of Sabouraud dextrose broth in a round-bottom 96-well plate. The *C. albicans* cultures were supplemented with KSL-W at concentrations of 1, 10, 25, 50, 75, and 100 µg/ml. The negative controls were *C. albicans* cultures not supplemented with KSL-W, while the positive controls were *C. albicans* cultures supplemented with amphotericin B at concentrations of 1, 5, and 10 µg/ml. The plates were incubated for 5, 10, and

**Table 4 Gene expression (3 h) under hyphae inducing culture conditions (medium supplemented with 10% fetal calf serum, with culture incubation at 37°C)**

Gene	Untreated <i>C. albicans</i>	Amphotericin B		KSL-W 25 µg/ml		KSL-W 100 µg/ml	
	Fold change <sup>1</sup>	Fold change <sup>1</sup>	p-value <sup>2</sup>	Fold change <sup>1</sup>	p-value <sup>2</sup>	Fold change <sup>1</sup>	p-value <sup>2</sup>
<i>SAP2</i>	0.99	3.36	0.003	0.78	0.02	0.62	0.003
<i>SAP4</i>	0.96	2.41	0.02	0.44	0.0002	0.24	< 0.0001
<i>SAP5</i>	1.00	0.49	0.0007	0.83	0.03	0.01	< 0.0001
<i>SAP6</i>	1.00	2.56	0.01	0.30	< 0.0001	0.11	< 0.0001
<i>EAP1</i>	1.00	6.06	< 0.001	1.06	0.4	0.99	0.8
<i>EFG1</i>	1.00	1.09	0.6	0.55	0.0004	0.66	0.02
<i>NRG1</i>	1.00	2.45	0.01	0.66	0.0006	0.64	0.0005
<i>HWP1</i>	1.00	0.0055	< 0.001	0.078	< 0.0001	0.0035	< 0.0001

<sup>1</sup>Fold change was calculated by PCR product of the gene of interest/the PCR product of ACT1 (the house keeping gene), and normalized to the negative control of untreated *C. albicans* where the expression was considered equal to 1.

<sup>2</sup>P-values were obtained after comparison of test to negative control (untreated *C. albicans*).

**Table 5 Gene expression (6 h) under hyphae inducing culture conditions (medium supplemented with 10% fetal calf serum, with culture incubation at 37°C)**

Gene	Untreated <i>C. albicans</i>	Amphotericin B		KSL-W 25 µg/ml		KSL-W 100 µg/ml	
	Fold change <sup>1</sup>	Fold change <sup>1</sup>	p-value <sup>2</sup>	Fold change <sup>1</sup>	p-value <sup>2</sup>	Fold change <sup>1</sup>	p-value <sup>2</sup>
<i>SAP2</i>	0.99	8.17	0.009	0.7	0.2	1.31	0.02
<i>SAP4</i>	0.96	2.58	0.03	0.73	0.04	0.72	0.04
<i>SAP5</i>	1.00	0.72	0.007	0.83	0.0004	0.56	0.006
<i>SAP6</i>	1.00	4.01	0.02	0.58	0.01	0.68	0.04
<i>EAP1</i>	1.00	6.36	0.001	0.44	0.008	0.73	0.003
<i>EFG1</i>	1.00	1.78	0.048	0.31	< 0.0001	0.47	0.01
<i>NRG1</i>	1.00	3.97	0.0005	0.37	0.001	0.37	0.05
<i>HWP1</i>	1.00	0.008	< 0.001	0.09	0.001	0.03	< 0.0001

<sup>1</sup>Fold change was calculated by PCR product of the gene of interest/the PCR product of ACT1 (the house keeping gene), and normalized to the negative control of untreated *C. albicans* where the expression was considered equal to 1.

<sup>2</sup>P-values were obtained after comparison of test to negative control (untreated *C. albicans*).

15 h prior to cell growth analyses. *C. albicans* growth was assessed using the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) MTT assay (Sigma-Aldrich) which measures cell growth as a function of mitochondrial activity [64]. Briefly, an MTT stock solution (5 mg/ml) was prepared in PBS and added to each culture at a final concentration of 10% (v/v). The *C. albicans* cultures were then incubated with the MTT solution at 30°C for 4 h, after which time the plate was centrifuged for 10 min at 1200 rpm and the supernatant was removed. The remaining pellet from each well was then washed with warm PBS, with 200 µl of 0.04 N HCl in isopropanol added to each well, followed by another incubation for 15 min. Absorbance (optical density, OD) was subsequently measured at 550 nm by means of an xMark microplate spectrophotometer (Bio-Rad, Mississauga, ON, Canada). Results are reported as means ± SD of three separate experiments.

#### Effect of KSL-W on *C. albicans* transition from blastospore to hyphal form

To determine the effect of KSL-W on the yeast-to-hyphae transition, *C. albicans* (10<sup>5</sup> cells) was first grown in 500 ml of Sabouraud dextrose broth supplemented with 0.1% glucose and 10% fetal bovine serum (FBS). KSL-W was then added (or not) to the culture at various concentrations (1, 5, 10, 15, and 25 µg/ml). The negative controls were the *C. albicans* cultures without antimicrobial peptide, while the positive controls represented the *C. albicans* cultures supplemented with amphotericin B (1, 5, and 10 µg/ml). The hyphae-inducing conditions were previously reported [65], consisting of culture medium supplementation with 10% fetal calf serum and subsequent incubation at 37°C. These conditions were used in our experiments. Following incubation for 4 or 8 h, the cultures were observed microscopically and photographed to record *C. albicans*

morphology (n = 5) and the density of *C. albicans* transition was measured.

#### Effect of KSL-W on *C. albicans* gene activation/repression

*C. albicans* was subcultured overnight in Sabouraud liquid medium supplemented with 0.1% glucose, pH 5.6, in a shaking water bath for 18 h at 30°C. The yeast cells were then collected, washed with PBS, and counted with a hemocytometer, after which time they were co-cultured with or without the antimicrobial peptide under hyphae- or non-hyphae-inducing conditions, as follows.

#### Effect of KSL-W on gene activation when *C. albicans* was cultured under non-hyphae-inducing conditions

*C. albicans* was co-cultured with either KSL-W (1, 25, 100 µg/ml) or amphotericin B (1 µg/ml) or with none of these molecules (controls) in Sabouraud liquid medium supplemented with 0.1% glucose, pH 5.6. The cultures were maintained at 30°C for 3 and 6 h.

#### Effect of KSL-W on gene activation when *C. albicans* were cultured under hyphae-inducing conditions

*C. albicans* was co-cultured with either KSL-W (1, 25, 100 µg/ml) or amphotericin B (1 µg/ml) or with none of these molecules (controls) in Sabouraud liquid medium supplemented with 0.1% glucose, pH 5.6. As previously reported, to promote the transition of *C. albicans* from blastospore to hyphal form, the culture medium was supplemented with 10% fetal calf serum and the incubation was performed for 3 and 6 h at 37°C. Following each culture period under both conditions [68], the cultures were centrifuged 10 min at 13,000 rpm, the supernatants were discarded, and each pellet was suspended thereafter in 0.6 ml of lysis buffer (Glycerol 1 M, EDTA 0.1 M). Glass beads (0.425–0.6 mm in diameter; 0.2 ml) were added to each suspended pellet prior to sonication (4 × 1 min, followed by 2 min of incubation in ice) with

a MiniBead-beater (Biospec Products, Bartlesville, OK, USA). Following cell lysis, the total RNA was extracted from each sample by means of the Illustra RNAspin Mini kit (GE Health Care UK Limited, Buckingham, UK). Concentration, purity, and quality of the isolated RNA were determined using the Experion system and RNA StdSens analysis kit according to the instructions provided by the manufacturer (Bio-Rad, Hercules, CA, USA).

#### Quantitative real-time RT-PCR

The RNA (500 ng of each sample) was reverse transcribed into cDNA by means of the iScript cDNA Synthesis kit (Bio-Rad, Mississauga, ON, Canada). The conditions for the preparation of the cDNA templates for PCR analysis were 5 min at 25°C, 1 h at 42°C, and 5 min at 85°C. Quantitative PCR (qPCR) was carried out as previously described [36]. The quantity of mRNA transcripts was measured with the Bio-Rad CFX96 real-time PCR detection system. Reactions were performed using a PCR supermix, also from Bio-Rad (iQ SYBR Green supermix). Primers (Table 6) were added to the reaction mix to a final concentration of 250 nM. Five microliters of each cDNA sample were added to a 20 µl PCR mixture containing 12.5 µl of the iQ SYBR Green supermix, 0.5 µl of specific primers ACT1, SAP2, SAP4, SAP5, SAP6, HWP1, and EAP1 (Midland Certified Reagent Company, Inc., Midland, TX, USA), as well as

EFG1 and NRG1 (Invitrogen Life Technologies Inc., Burlington, ON, Canada), and 7 µl of RNase/DNase-free water (MP Biomedicals, Solon, OH, USA). Each reaction was performed in a Bio-Rad MyCycler Thermal Cycler. For the qPCR, the CT was automatically determined using the accompanying Bio-Rad CFX Manager. The thermocycling conditions for the ACT1, SAPs 2-4-5-6, and EAP1 were established as 5 min at 95°C, followed by 30 cycles of 15 s at 95°C, 30 s at 60°C, and 30 s at 72°C, with each reaction performed in triplicate. For the EFG1 and NRG1, the thermocycling conditions were set for 3 min at 95°C, followed by 45 cycles of 10 s at 95°C, 40 s at 54°C, and 40 s at 72°C, with each reaction also performed in triplicate. For the HWP1, the conditions were 3 min at 95°C, followed by 45 cycles of 10 s at 95°C, 30 s at 54°C, and 40 s at 72°C, with each reaction performed in triplicate. The specificity of each primer pair was determined by the presence of a single melting temperature peak. The ACT1 produced uniform expression levels varying by less than 0.5 CTs between sample conditions and thus became the reference gene for this study. The results were analyzed by means of the  $2^{-\Delta\Delta C_t}$  (Livak) relative expression method.

#### Effect of KSL-W on *C. albicans* biofilm formation

*C. albicans* biofilms were obtained by culturing the yeast on a porous collagen scaffold which facilitated *C. albicans* penetration through the pores and its adhesion to the scaffold through collagen affinity. This also promoted biofilm formation and handling with no cell loss, thus contributing to maintaining the biofilm structure. For this purpose, 5 mm × 5 mm samples of porous scaffold (Collatape, Zimmer Dental Inc., Carlsbad, CA, USA) were placed into a 24-well plate. The scaffolds were then rinsed twice with culture medium, seeded with *C. albicans* ( $10^5$  cells), and incubated for 30 min at 30°C without shaking to allow for adherence. Fresh Sabouraud medium was added to each well in the presence or absence of various concentrations of KSL-W (1, 10, 25, 50, 75, and 100 µg/ml). Two controls were included in this study: the negative control was *C. albicans* seeded without KSL-W, while the positive control was *C. albicans* seeded with amphotericin B (1, 5, and 10 µg/ml). The *C. albicans*-seeded scaffolds were then incubated for 2, 4, and 6 days at 30°C. The medium, KSL-W, and amphotericin B were refreshed every 48 h. Following each culture period, *C. albicans* growth and biofilm formation was assessed by scanning electron microscopy and XTT-menadione assay.

#### Scanning electron microscopy (SEM) analysis

Biofilms were fixed in ethylene glycol for 60 min and rinsed once with sterile PBS. Dehydration was performed in a series of 5-min treatments with ethanol

**Table 6 Primer sequences used for the qRT-PCR**

Gene	Primer sequence 5' to 3'	Amp size (bp)
ACT1	Forward : GCTGGTAGAGACTTGACCAACCA	87
	Reverse : GACAATTTCTCTTTCAGCACTAGTAGTGA	
SAP2	Forward : TCCTGATGTTAATGTTGATTGTCAAG	82
	Reverse : TGGATCATATGTCCCCTTTTGT	
SAP4	Forward : AGATATTGAGCCACAGAAATTCC	82
	Reverse : CAATTTAACTGCAACAGTCCCTCTT	
SAP5	Forward : CAGAATTTCCCGTCGATGAGA	78
	Reverse : CATTGTGCAAAGTAACTGCAACAG	
SAP6	Forward : TTACGCAAAGGTAACCTGTATCAAGA	102
	Reverse : CCTTTATGAGCACTAGTAGACCAAACG	
ALS3	Forward : AATGGTCCTTATGAATCACCATCTACTA	51
	Reverse : GAGTTTTTCATCCATACTTGATTTCACAT	
HWP1	Forward : GCTCAACTTATTGCTATCGCTTATTACA	67
	Reverse : GACCGTCTACTCTGTGGGACAGT	
EAP1	Forward : CTGCTCACTCAACTCAATTGTCG	51
	Reverse : GAACACATCCACCTTCGGGA	
EFG1	Forward : TATGCCCCAGCAAACAACCTG	202
	Reverse : TTGTTGCTCTGCTGTCTGTC	
NRG1	Forward : CACCTCACTTGCAACCCC	198
	Reverse : GCCCTGGAGATGGTCTGA	

solutions of increasing concentration (50, 70, 90, and twice at 100%). The dehydrated biofilms were kept overnight in a vacuum oven at 25°C, after which time they were sputter-coated with gold, examined, and imaged (n = 4) under a JEOL 6360 LV SEM (Soquelec, Montréal, QC, Canada) operating at a 30 kV accelerating voltage.

#### **XTT reduction assay**

To support the hypothesis that KSL-W quantitatively affects *C. albicans* biofilms, an XTT reduction assay was performed on the KSL-W-treated and control biofilms at defined time points. XTT assay is one of the most useful and accurate methods to investigate microbial biofilm formation. The metabolic activity of the biofilm cells was measured as a reflection of viable cell count. To do so, *C. albicans* biofilms formed in the porous scaffold with or without KSL-W treatments for 2, 4, and 6 days were subjected to an XTT assay. Fifty microliters of XTT salt solution (1 mg/ml in PBS; Sigma-Aldrich) and 4 µl of menadione solution (1 mM in acetone; Sigma-Aldrich) were added to wells containing 4 ml of sterile PBS. The biofilms were then added to the mixture and the plates were incubated at 37°C for 5 h, after which time the supernatant was collected to measure the XTT formazan at 492 nm by means of an xMark microplate spectrophotometer (Bio-Rad, Mississauga, ON, Canada).

#### **Effect of KSL-W on the disruption of mature *C. albicans* biofilms**

Mature *C. albicans* biofilms were obtained by culturing *C. albicans* (10<sup>5</sup>) on a porous 3D collagen scaffold for 6 days at 30°C in Sabouraud liquid medium supplemented with 0.1% glucose at pH 5.6. The culture medium was refreshed every 2 days. At the end of the 6-day culture period, the biofilms were treated (or not) with KSL-W (75 and 100 µg/ml). Amphotericin B-treated biofilms (1, 5, and 10 µg/ml) were used as the positive controls. The biofilms were continuously incubated (or not) with either KSL-W or amphotericin B for 2, 4, and 6 days, with medium changing every day. KSL-W and amphotericin B were also refreshed at each medium changing. Following each incubation period, SEM and XTT analyses were performed, as described above.

#### **Statistical analysis**

Each experiment was performed at least four times, with experimental values expressed as means ± SD. The statistical significance of the differences between the control (absence of KSL-W) and test (presence of KSL-W or amphotericin B) values was determined by means of a one-way ANOVA. Posteriori comparisons were performed using Tukey's method. Normality and variance

assumptions were verified using the Shapiro-Wilk test and the Brown and Forsythe test, respectively. All of the assumptions were fulfilled. P values were declared significant at ≤ 0.05. The data were analyzed using the SAS version 8.2 statistical package (SAS Institute Inc., Cary, NC, USA).

#### **Authors' contributions**

MR, KPL, and AS designed the experiments, supervised the research and wrote the paper. ST, AA, and AS performed the experiments and data analyses and contributed to the writing of the paper. Each author read and approved the final manuscript.

#### **Acknowledgements**

This study was supported financially by the United States Army Medical Research and Materiel Command (Award number ERMS No. 12304006) and by a grant from the Fonds Émile-Beaulieu, a Université Laval foundation. The authors also thank Ms. Claire Kingston (Traduction CFK) for proofreading and editing this manuscript.

#### **DOD Disclaimer**

One of the authors (KPL) is a United States Government employee. The work presented is part of his official duties. The opinions or assertions contained herein are the personal views of these authors and are not to be construed as official or reflecting the views of the United States Army or Department of Defense.

#### **Author details**

<sup>1</sup>Oral Ecology Research Group, Faculty of Dentistry, Laval University, 2420, rue de la Terrasse, Quebec G1V 0A6, QC, Canada. <sup>2</sup>Department of Biochemistry, Genome Research Chair, College of Science King Saud University, Riyadh, Kingdom of Saudi Arabia. <sup>3</sup>Dental and Trauma Research Detachment, US Army Institute of Surgical Research, JBSA Fort Sam Houston, San Antonio, TX, USA.

Received: 5 July 2013 Accepted: 4 November 2013

Published: 7 November 2013

#### **References**

1. Arendorf TM, Walker DM: The prevalence and intra-oral distribution of *Candida albicans* in man. *Arch Oral Biol* 1980, **25**:1–10.
2. Cannon RD, Chaffin WL: Oral colonization by *Candida albicans*. *Crit Rev Oral Biol Med* 1999, **10**:359–383.
3. Sudbery P, Gow N, Berman J: The distinct morphogenic states of *Candida albicans*. *Trends Microbiol* 2004, **12**:317–324.
4. Nobile CJ, Nett JE, Andes DR, Mitchell AP: Function of *Candida albicans* adhesin Hwp1 in biofilm formation. *Eukaryot Cell* 2006, **5**:1604–1610.
5. Li F, Palecek SP: *EAP1*, a *Candida albicans* gene involved in binding human epithelial cells. *Eukaryot Cell* 2003, **2**:1266–1273.
6. Sohn K, Urban C, Brunner H, Rupp S: *EFG1* is a major regulator of cell wall dynamics in *Candida albicans* as revealed by DNA microarrays. *Mol Microbiol* 2003, **47**:89–102.
7. Stoldt VR, Sonneborn A, Leuker CE, Ernst JF: *Efg1p*, an essential regulator of morphogenesis of the human pathogen *Candida albicans*, is a member of a conserved class of bHLH proteins regulating morphogenetic processes in fungi. *EMBO J* 1997, **16**:1982–1991.
8. Lo HJ, Köhler JR, DiDomenico B, Loebeberg D, Cacciapuoti A, Fink GR: Nonfilamentous *C. albicans* mutants are avirulent. *Cell* 1997, **90**:939–949.
9. Schaller M, Borelli C, Korting HC, Hube B: Hydrolytic enzymes as virulence factors of *Candida albicans*. *Mycoses* 2005, **48**:365–377.
10. Décanis N, Tazi N, Correia A, Vilanova M, Rouabhia M: Farnesol, a fungal quorum-sensing molecule triggers *Candida albicans* morphological changes by down-regulating the expression of different secreted aspartyl proteinase genes. *Open Microbiol J* 2011, **5**:119–126.
11. Naglik JR, Challacombe SJ, Hube B: *Candida albicans* secreted aspartyl proteinases in virulence and pathogenesis. *Microbiol Mol Biol Rev* 2003, **67**:400–428.
12. Hube B, Naglik J: *Candida albicans* proteinases: resolving the mystery of a gene family. *Microbiology* 2001, **147**:1997–2005.

13. White TC, Miyasaki SH, Agabian N: Three distinct secreted aspartyl proteinases in *Candida albicans*. *J Bacteriol* 1993, **175**:6126–6133.
14. White TC, Agabian N: *Candida albicans* secreted aspartyl proteinases: isoenzyme pattern is determined by cell type, and levels are determined by environmental factors. *J Bacteriol* 1995, **177**:5215–5221.
15. Albrecht A, Felk A, Pichova I, Naglik JR, Schaller M, de Groot P, MacCallum D, Odds FC, Schäfer W, Klis F, Monod M, Hube B: Glycosylphosphatidylinositol-anchored proteases of *Candida albicans* target proteins necessary for both cellular processes and host-pathogen interactions. *J Biol Chem* 2006, **281**(2):688–694.
16. van der Weerden NL, Bleackley MR, Anderson MA: Properties and mechanisms of action of naturally occurring antifungal peptides. *Cell Mol Life Sci* 2013, **70**(19):3545–3570.
17. Fjell CD, Hiss JA, Hancock RE, Schneider G: Designing antimicrobial peptides: form follows function. *Nat Rev Drug Discov* 2012, **11**:37–51.
18. Seo MD, Won HS, Kim JH, Mishig-Ochir T, Lee BJ: Antimicrobial peptides for therapeutic applications: a review. *Molecules* 2012, **17**:12276–12286.
19. Campbell EL, Serhan CN, Colgan SP: Antimicrobial aspects of inflammatory resolution in the mucosa: a role for proresolving mediators. *J Immunol* 2011, **187**:3475–3481.
20. Lehrer RI, Lu W: alpha-Defensins in human innate immunity. *Immunol Rev* 2012, **245**:84–112.
21. Mehra T, Koberle M, Braunsdorf C, Mailander-Sanchez D, Borelli C, et al: Alternative approaches to antifungal therapies. *Exp Dermatol* 2012, **21**:778–782.
22. Zhu S: Discovery of six families of fungal defensin-like peptides provides insights into origin and evolution of the CSalphabeta defensins. *Mol Immunol* 2008, **45**:828–838.
23. Batoni G, Maisetta G, Brancatisano FL, Esin S, Campa M: Use of antimicrobial peptides against microbial biofilms: advantages and limits. *Curr Med Chem* 2011, **18**:256–279.
24. Dziarski R, Gupta D: Review: Mammalian peptidoglycan recognition proteins (PGRPs) in innate immunity. *Innate Immun* 2010, **16**:168–174.
25. Taraszewicz A, Fila G, Grinholc M, Nakonieczna J: Innovative strategies to overcome biofilm resistance. *Biomed Res Int* 2013, **2013**:150653. doi: 10.1155/2013/150653.
26. Cota-Arriola O, Cortez-Rocha MO, Burgos-Hernandez A, Ezquerro-Brauer JM, Plascencia-Jatomea M: Controlled release matrices and micro/nanoparticles of chitosan with antimicrobial potential: development of new strategies for microbial control in agriculture. *J Sci Food Agric* 2013, **93**:1525–1536.
27. Dhople V, Krukemeyer A, Ramamoorthy A: The human beta-defensin-3, an antibacterial peptide with multiple biological functions. *Biochim Biophys Acta* 2006, **1758**:1499–1512.
28. Joly S, Maze C, McCray PB Jr, Guthmiller JM: Human beta-defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms. *J Clin Microbiol* 2004, **42**:1024–1029.
29. Mooney C, Haslam NJ, Pollastri G, Shields DC: Towards the improved discovery and design of functional peptides: common features of diverse classes permit generalized prediction of bioactivity. *PLoS One* 2012, **7**:e45012.
30. Na DH, Faraj J, Capan Y, Leung KP, DeLuca PP: Stability of antimicrobial decapeptide (KSL) and its analogues for delivery in the oral cavity. *Pharm Res* 2007, **24**:1544–1550.
31. Hong SY, Park TG, Lee KH: The effect of charge increase on the specificity and activity of a short antimicrobial peptide. *Peptides* 2001, **22**:1669–1674.
32. Oh JE, Hong SY, Lee KH: Structure-activity relationship study: short antimicrobial peptides. *J Pept Res* 1999, **53**:41–46.
33. Concannon SP, Crowe TD, Abercrombie JJ, Molina CM, Hou P, et al: Susceptibility of oral bacteria to an antimicrobial decapeptide. *J Med Microbiol* 2003, **52**:1083–1093.
34. Leung KP, Crowe TD, Abercrombie JJ, Molina CM, Bradshaw CJ, et al: Control of oral biofilm formation by an antimicrobial decapeptide. *J Dent Res* 2005, **84**:1172–1177.
35. Baker PJ, Coburn RA, Genco RJ, Evans RT: The in vitro inhibition of microbial growth and plaque formation by surfactant drugs. *J Periodontal Res* 1978, **13**:474–485.
36. Semlali A, Leung KP, Curt S, Rouabhia M: Antimicrobial decapeptide KSL-W attenuates *Candida albicans* virulence by modulating its effects on Toll-like receptor, human  $\beta$ -defensin, and cytokine expression by engineered human oral mucosa. *Peptides* 2011, **32**(5):859–867.
37. Okkers DJ, Dicks LM, Silvester M, Joubert JJ, Odendaal HJ: Characterization of pentocin TV35b, a bacteriocin-like peptide isolated from *Lactobacillus pentosus* with a fungistatic effect on *Candida albicans*. *J Appl Microbiol* 1999, **87**:726–734.
38. Dixon DR, Jeffrey NR, Dubey VS, Leung KP: Antimicrobial peptide inhibition of *Porphyromonas gingivalis* 381-induced hemagglutination is improved with a synthetic decapeptide. *Peptides* 2009, **30**:2161–2167.
39. Raines SM, Rane HS, Bernardo SM, Binder JL, Lee SA, et al: Deletion of Vacuolar Proton-translocating ATPase Voa Isoforms Clarifies the Role of Vacuolar pH as a Determinant of Virulence-associated Traits in *Candida albicans*. *J Biol Chem* 2013, **288**:6190–6201.
40. Ariyachet C, Solis NV, Liu Y, Prasadarao NV, Filler SG, et al: SR-Like RNA-Binding Protein Slr1 Affects *Candida albicans* Filamentation and Virulence. *Infect Immun* 2013, **81**:1267–1276.
41. Décanis N, Savignac K, Rouabhia M: Farnesol promotes epithelial cell defense against *Candida albicans* through Toll-like receptor 2 expression, interleukin-6 and human beta-defensin 2 production. *Cytokine* 2009, **45**:132–140.
42. Zhang J, Silao FG, Bigol UG, Bungay AA, Nicolas MG, et al: Calcineurin is required for pseudohyphal growth, virulence, and drug resistance in *Candida lusitanae*. *PLoS One* 2012, **7**:e44192.
43. Koshlukova SE, Araujo MWB, Baev D, Edgerton M: Released ATP is an extracellular cytotoxic mediator in salivary histatin 5-induced killing of *Candida albicans*. *Infect Immun* 2000, **68**:6848–6856.
44. Vylkova S, Jang WS, Li W, Nayyar N, Edgerton M: Histatin 5 initiates osmotic stress response in *Candida albicans* via activation of the Hog1 mitogen-activated protein kinase pathway. *Eukaryot Cell* 2007, **6**:1876–1888.
45. Jang WS, Bajwa JS, Sun JN, Edgerton M: Salivary histatin 5 internalization by translocation, but not endocytosis, is required for fungicidal activity in *Candida albicans*. *Mol Microbiol* 2010, **77**:354–370.
46. Ramage G, Vandewalle K, Wickes BL, Lopez-Ribot JL: Characteristics of biofilm formation by *Candida albicans*. *Rev Iberoam Micol* 2001, **18**:163–170.
47. Banerjee M, Uppuluri P, Zhao XR, Carlisle PL, Vipulanandan G, et al: Expression of UME6, a key regulator of *Candida albicans* hyphal development, enhances biofilm formation via Hgc1- and Sun41-dependent mechanisms. *Eukaryot Cell* 2013, **12**:224–232.
48. da Silva BR, de Freitas VA, Carneiro VA, Arruda FV, Lorenzon EN, et al: Antimicrobial activity of the synthetic peptide Lys-a1 against oral streptococci. *Peptides* 2013, **42**:78–83.
49. Beckloff N, Laube D, Castro T, Furgang D, Park S, et al: Activity of an antimicrobial peptide mimetic against planktonic and biofilm cultures of oral pathogens. *Antimicrob Agents Chemother* 2007, **51**:4125–4132.
50. Patrzykat A, Friedrich CL, Zhang L, Mendoza V, Hancock RE: Sublethal concentrations of pleurocidin-derived antimicrobial peptides inhibit macromolecular synthesis in *Escherichia coli*. *Antimicrob Agents Chemother* 2002, **46**:605–614.
51. Mason AJ, Chotimah IN, Bertani P, Bechinger B: A spectroscopic study of the membrane interaction of the antimicrobial peptide Pleurocidin. *Mol Membr Biol* 2006, **23**:185–194.
52. Bauerova V, Pichova I, Hruskova-Heidingsfeldova O: Nitrogen source and growth stage of *Candida albicans* influence expression level of vacuolar aspartic protease Apr1p and carboxypeptidase Cpy1p. *Can J Microbiol* 2012, **58**:678–681.
53. Cleary IA, Lazzell AL, Monteagudo C, Thomas DP, Saville SP: BRG1 and NRG1 form a novel feedback circuit regulating *Candida albicans* hypha formation and virulence. *Mol Microbiol* 2012, **85**:557–573.
54. Nobile CJ, Fox EP, Nett JE, Sorrells TR, Mitrovich QM, et al: A recently evolved transcriptional network controls biofilm development in *Candida albicans*. *Cell* 2012, **148**:126–138.
55. Murad AM, Leng P, Straffon M, Wishart J, Macaskill S, et al: NRG1 represses yeast-hypha morphogenesis and hypha-specific gene expression in *Candida albicans*. *EMBO J* 2001, **20**:4742–4752.
56. Braun BR, Kadosh D, Johnson AD: NRG1, a repressor of filamentous growth in *C. albicans*, is down-regulated during filament induction. *EMBO J* 2001, **20**:4753–4761.
57. Li F, Svarovsky MJ, Karlsson AJ, Wagner JP, Marchillo K, et al: Eap1p, an adhesin that mediates *Candida albicans* biofilm formation in vitro and in vivo. *Eukaryot Cell* 2007, **6**:931–939.
58. Sharkey LL, McNemar MD, Saporito-Irwin SM, Sypherd PS, Fonzi WA: HWP1 functions in the morphological development of *Candida albicans* downstream of EFG1, TUP1, and RBF1. *J Bacteriol* 1999, **181**:5273–5279.
59. Staniszewska M, Bondaryk M, Siennicka K, Kurek A, Orłowski J, et al: In vitro study of secreted aspartyl proteinases Sap1 to Sap3 and Sap4 to Sap6



- expression in *Candida albicans* pleomorphic forms. *Pol J Microbiol* 2012, **61**:247–256.
60. Lian CH, Liu WD: Differential expression of *Candida albicans* secreted aspartyl proteinase in human vulvovaginal candidiasis. *Mycoses* 2007, **50**:383–390.
61. Hube B, Monod M, Schofield DA, Brown AJ, Gow NA: Expression of seven members of the gene family encoding secretory aspartyl proteinases in *Candida albicans*. *Mol Microbiol* 1994, **14**:87–99.
62. Puri S, Kumar R, Chadha S, Tati S, Conti HR, *et al*: Secreted aspartic protease cleavage of *Candida albicans* Msb2 activates Cek1 MAPK signaling affecting biofilm formation and oropharyngeal candidiasis. *PLoS One* 2012, **7**:e46020.
63. Hong SY, Oh JE, Kwon M, Choi MJ, Lee JH, *et al*: Identification and characterization of novel antimicrobial decapeptides generated by combinatorial chemistry. *Antimicrob Agents Chemother* 1998, **42**:2534–2541.
64. Denizot F, Lang R: Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. *J Immunol Methods* 1986, **89**:271–277.
65. Li L, Zhang C, Konopka JB: A *Candida albicans* temperature-sensitive *cdc12-6* mutant identifies roles for septins in selection of sites of germ tube formation and hyphal morphogenesis. *Eukaryot Cell* 2012, **11**:1210–1218.

doi:10.1186/1471-2180-13-246

**Cite this article as:** Theberge *et al.*: *C. albicans* growth, transition, biofilm formation, and gene expression modulation by antimicrobial decapeptide KSL-W. *BMC Microbiology* 2013 **13**:246.

Submit your next manuscript to BioMed Central  
and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)



**Antimicrobial peptide KSL-W promotes gingival fibroblast growth, migration, and defense against Streptococcus mutans infection**

Journal:	<i>Applied Microbiology</i>
Manuscript ID	JAM-2016-0404
Journal Name:	Journal of Applied Microbiology
Manuscript Type:	JAM - Original Article
Date Submitted by the Author:	23-Feb-2016
Complete List of Authors:	Park, Hyun Jin; University of Laval, Dental medicine Salim, Mabrouka; University of Laval, Dental medicine Semlali, Abdelhabib; asemjali@KSU.EDU.SA, Dep. Biochemistry Leung, Kai ; US Army Institute of Surgical Research, Dental and Craniofacial Trauma Research ROUABHIA, Mahmoud; University of Laval, Dental medicine;
Key Words:	Antimicrobials, Cytotoxicity, Infection, Peptides, Streptococci

1  
2  
3 **Antimicrobial peptide KSL-W promotes gingival fibroblast growth, migration, and defense**  
4 **against *Streptococcus mutans* infection**  
5  
6  
7  
8  
9

10  
11 Hyun-Jin Park<sup>1</sup>, Mabrouka Salem<sup>1</sup>, Abdelhabib Semlali<sup>2</sup>, Kai P Leung<sup>3</sup>, Mahmoud Rouabhia<sup>1</sup>  
12  
13

14  
15  
16  
17  
18 <sup>1</sup>Groupe de Recherche en Écologie Buccale, Faculté de Médecine Dentaire, Université Laval,  
19 Québec, QC, Canada.

20  
21  
22  
23 <sup>2</sup>Department of Biochemistry, College of Science, King Saud University, Riyadh, Saudi Arabia.  
24  
25

26  
27 <sup>3</sup> Dental and Craniofacial Trauma Research and Tissue Regeneration Directorate, US Army  
28 Institute of Surgical Research, Joint Base Fort Sam Houston, TX 78234-6315  
29  
30  
31  
32  
33  
34  
35  
36

37 **Running title:** KSL-W promotes wound healing and prevents infection  
38  
39  
40  
41  
42  
43

44 Corresponding author at: Université Laval, Groupe de recherche en écologie buccale, Faculté de  
45 médecine dentaire, Pavillon de Médecine dentaire, 2420, rue de la Terrasse Université Laval  
46 Québec, Québec G1V 0A6, Canada.  
47  
48

49  
50 Tel.: +1 418 656 2131/16321; fax: +1 418 656 2861.  
51

52  
53 E-mail address: [Mahmoud.Rouabhia@fmd.ulaval.ca](mailto:Mahmoud.Rouabhia@fmd.ulaval.ca) (M. Rouabhia).  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Aim:** The aim of this study was to investigate the interaction between primary human gingival fibroblasts and KSL-W, an antimicrobial peptide, and the effect of this peptide on gingival fibroblast defense *in vitro* against *Streptococcus mutans*.

**Material and Methods:** Primary human gingival fibroblasts were used to study the effect of KSL-W peptide on cell adhesion, growth and the secretion of metalloproteinase (MMP). We also investigated the effect of KSL-W on fibroblast migration by mean of scratch assay. Finally we analyzed the effect of antimicrobial activity of KSL-W on *S. mutans* infected fibroblast cultures

**Results:** The peptide KSL-W promoted fibroblast growth by increasing the S and G2/M cell cycle phases. Peptide KSL-W also regulated the secretion of metalloproteinase (MMP)-1 and -2, through MMP inhibitors such as tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2. Using an *in vitro* wound healing assay, we demonstrated that peptide KSL-W promoted fibroblast migration as compared to non-treated cultures. The addition of KSL-W peptide to *S. mutans* infected fibroblast culture prevents adverse effect of the bacteria through fibroblast growth and IL-8 secretion.

**Conclusion:** These findings therefore show that peptide KSL-W was safe to use with human cells, as it promoted their growth and migration and attenuated *S. mutans* virulence by decreasing its effect on cell viability and IL-8 secretion.

**Significance and Impact:** This study points to the possibility of using KSL-W as antimicrobial peptide, and as a peptide accelerating the wound healing process.

**Keywords:**

Antimicrobial peptide; KSL-W; Gingival fibroblasts; Cell migration; Cell cycle; Interleukin;  
*Streptococcus mutans*

**Introduction**

The human body contains millions of microorganisms involved in maintaining health. However, some of these microorganisms are capable of eliciting diseases in a different microenvironment when moving from their normal location of residence (Turnbaugh *et al.*, 2007; Ling *et al.*, 2010). Throughout the body, various microhabitats contribute to the overall microbiome. The oral cavity, skin, and gut each contain its own microbiome maintaining commensal and symbiotic interactions with the host (Sonnenburg and Fischbach, 2011). In the oral cavity, over 700 species of bacteria have been identified; these bacterial species benefit within the oral cavity, residing on both the hard and soft tissues to interact and form microbial biofilms (Cavalcanti *et al.*, 2016; Ng *et al.*, 2015). The teeth, gingival sulcus, tongue, cheeks, hard and soft palates, and tonsils also provide enriching environments where microbial communities can adhere, multiply, form biofilms, and potentially induce diseases (Dewhirst *et al.*, 2010).

The main factors responsible for initiating microbial oral disease are poor oral hygiene and immune system dysfunctionality (Al-Ahmad *et al.*, 2010). Uncontrolled oral hygiene is known to promote microorganism accumulation within biofilm. Failure to remove accumulating biofilm leads to bacterial overgrowth (which may become pathogenic), a reduction of microbial biodiversity, and ultimately, the development of diseases such as dental caries or periodontal disease (Al-Ahmad *et al.*, 2010; Zaura *et al.*, 2009). A deficient immune system may also be

1  
2  
3 attractive to microbial infection. As the immune system regulates interactions between the  
4  
5 microbiome and the host, a compromised system usually disturbs mutual or commensal  
6  
7 relationships (Patil *et al.*, 2015; Nguyen *et al.*, 2015).  
8  
9

10  
11  
12 Oral diseases, such as dental caries and periodontal disease, are among the most prevalent  
13  
14 diseases worldwide (Horz *et al.*, 2007; Hajishengalliset *al.*, 2015), affecting nearly all ages and  
15  
16 geographic populations. Although a specific microbiome contributing to the development of  
17  
18 dental caries has yet to be established (Ling *et al.*, 2010), the most common bacteria responsible  
19  
20 for dental caries are *S. mutans*, *S. sobrinus*, and *Lactobacillus acidophilus* (Fernández *et al.*,  
21  
22 2015, Johansson *et al.*, 2016).  
23  
24  
25  
26  
27  
28

29  
30 The oral cavity is the primary gateway to the human body; microorganisms inhabiting this area  
31  
32 are thus highly capable of spreading to different body sites (Dewhirst *et al.*, 2010). Pathogens  
33  
34 originating in the oral cavity have been detected in blood cultures and are known to destroy the  
35  
36 oral mucosa to reach the circulation, leading to dissemination (Horz *et al.*, 2007). While such a  
37  
38 situation is rare with a healthy immune system, this does suggest the existence of a mechanism  
39  
40 by which pathogens derived from oral infections may lead to systemic body infection.  
41  
42  
43  
44

45  
46 The oral mucosa is the most important barrier against physical, microbial, and chemical agents  
47  
48 that cause local cell injury (Presland and Dale, 2000). The oral mucosa is also involved in the  
49  
50 proinflammatory process by producing cytokines and antimicrobial peptides, either constitutively  
51  
52 or following a variety of stimuli (Andrian *et al.*, 2005, Rouabhia *et al.*, 2005). This suggests that  
53  
54 the oral mucosa plays an active role in controlling oral infections and maintaining the symbiotic  
55  
56 relationship with oral microbial agents. Oral mucosal cells, namely, epithelial cells and  
57  
58  
59  
60

1  
2  
3 fibroblasts, interact with each other to maintain tissue integrity and function (Mahanonda *et al.*,  
4  
5 2009). Gingival fibroblasts, the predominant cell type inhabiting gingival connective tissue, take  
6  
7 on a critical role in remodeling and maintaining gingival structure and extracellular matrix (van  
8  
9 Beurden *et al.*, 2005; Barrientos *et al.*, 2008). These fibroblasts are also key contributors to tissue  
10  
11 repair and wound healing through their adhesion, migration, growth, and differentiation, as well  
12  
13 as their production of extracellular matrix (ECM) (van Beurden *et al.*, 2005; Barrientos *et al.*,  
14  
15 2008). During ECM remodeling, balance is crucial between matrix metalloproteinases (MMPs)  
16  
17 and tissue inhibitors of metalloproteinases (TIMPs) (Page-McCaw *et al.*, 2007). TIMPs and  
18  
19 MMPs are tightly regulated during normal wound healing, and their imbalance has been reported  
20  
21 following infection (Andrian *et al.*, 2007, Kanangat *et al.*, 2006).  
22  
23  
24  
25  
26  
27  
28

29 To prevent infection, gingival cells (epithelial cells and fibroblasts) secrete high levels of  
30  
31 proinflammatory cytokines, such as IL-1 $\beta$ , IL-6, and IL-8 (Mostefaoui *et al.*, 2004, Semlali *et al.*,  
32  
33 2011). They also produce antimicrobial peptides against the infecting agents. Human gingival  
34  
35 fibroblasts secrete several antimicrobial peptides, such as  $\beta$ -defensin-1, -2, -3, and -4 (Derradjia  
36  
37 *et al.*, 2015; Levón *et al.*, 2015; Noronha *et al.*, 2014), thus contributing to the defense against  
38  
39 various pathogenic microbes (Chen *et al.*, 2013; Guo *et al.*, 2012). Many synthetic antimicrobial  
40  
41 peptides mimicking the structure and function of naturally occurring antimicrobial peptides have  
42  
43 been developed as an additional therapeutic initiative, along with available antibiotics to prevent  
44  
45 and eliminate human microbial infections, and the need for new antimicrobial agents is a well-  
46  
47 documented issue related to world health (Fernandes *et al.*, 2006).  
48  
49  
50  
51  
52  
53  
54

55 Leung *et al.* reported that KKVVFVKVFK (KSL) may be a useful antimicrobial agent to inhibit  
56  
57 the growth of oral bacteria associated with caries development and early plaque formation (Leung  
58  
59  
60

1  
2  
3 *et al.*, 2005; Na *et al.*, 2005). Furthermore, KSL analogue KSL-W (H<sub>2</sub>N-Lys-Lys-Val-Val-Phe-  
4 TryVal-Lys-Phe-Lys-COOH) was shown to be stable against salivary trypsin-catalyzed cleavage  
5  
6 in the oral cavity, and was determined as the most promising candidate in terms of potential  
7  
8 therapeutic activity and safety in the gastrointestinal tract (Na *et al.*, 2007). To further investigate  
9  
10 the usefulness of peptide KSL-W, the aim of this study was to determine the interactions between  
11  
12 KSL-W and human gingival fibroblasts and the influence of this peptide on fibroblast behaviors  
13  
14 when in contact with bacteria (*S. mutans*).  
15  
16  
17  
18  
19  
20  
21  
22

## 23 **Materials and methods**

### 24 **Culture of Primary Human Gingival Fibroblast Cells**

25  
26 Normal human gingival fibroblasts (ScienCell Research Laboratories, Carlsbad, CA, USA) were  
27  
28 cultured in Dulbecco's modified Eagle's (DME) medium (Gibco-Thermo Fisher Scientific,  
29  
30 Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (FBS) (Wisent Inc., Saint-  
31  
32 Jean-Baptiste, QC, Canada). The medium was changed three times a week. When the culture  
33  
34 reached 90% confluence, the cells were detached from the flasks with a 0.05% trypsin (MP  
35  
36 Biomedicals LLC, Santa Ana, CA, USA)–0.1% ethylenediaminetetraacetic acid (EDTA) (Merck  
37  
38 KGaA, Darmstadt, Germany) solution, washed twice with phosphate-buffered saline (PBS), and  
39  
40 suspended in DME-supplemented medium at a final concentration of 10<sup>6</sup> cells/mL. Cells at the  
41  
42 third and fourth passages were used to perform the experiments.  
43  
44  
45  
46  
47  
48  
49  
50

### 51 **Antimicrobial Peptide**

52  
53 Peptide KSL-W was synthesized by standard solid-phase procedures (Hong *et al.*, 1998) with 9-  
54  
55 fluorenylmethoxycarbonyl (Fmoc) chemistry in an automatic peptide synthesizer (model 90,  
56  
57  
58  
59  
60



1  
2  
3 Advanced ChemTech, Louisville, KY, USA). The synthetic peptides were then purified by  
4 reverse-phase HPLC (series 1100, Agilent Technologies, Santa Clara, CA, USA) by means of a  
5 Vydac C18 column. Peptide purity was confirmed by MALDI-TOF (matrix-assisted laser  
6 desorption/ionization-time of flight) MS (AnaSpec, Fremont, CA, USA). The final product was  
7 stored in lyophilized format at -20°C until use. A KSL-W solution was subsequently prepared,  
8 filtered (0.22 um pore size), and used for the experiments.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

### 20 **Bacteria and Growth Conditions**

21  
22 *S. mutans* (ATCC 25175, Manassas, VA, USA) was used in this study. The bacteria was grown  
23 aerobically at 37°C in Todd-Hewitt broth (BBL Microbiology Systems, Cockeysville, MD, USA)  
24 supplemented with hemin (Sigma-Aldrich, St. Louis, MO, USA) (10 µg/mL) and vitamin K  
25 (Sigma-Aldrich) (10 µg/mL) (THB-HK). For experimental purposes, the *S. mutans* was cultured  
26 overnight, then diluted in THB-HK to obtain an optical density at 660 nm (OD<sub>660</sub>) of  
27 0.2 (corresponding to  $1 \times 10^8$  colony-forming units (CFU)/mL). Samples (100 µL) were then  
28 used to infect the gingival fibroblast monolayer cultures.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

### 42 **Effect of KSL-W on primary human gingival fibroblast adhesion**

43  
44 Prior to cell seeding, five sterile glass slides (Bellco Glass Inc., Vineland, NJ, USA) (0.05 mm in  
45 diameter) were inserted into each well of a non-adherent 6-well plate (Sarstedt, Nümbrecht,  
46 Germany). Primary human gingival fibroblasts were then seeded at  $2 \times 10^5$  cells/well in DME  
47 supplemented with 10% FBS. Immediately after seeding, various concentrations (0, 10, 50, or  
48 100 µg/mL) of peptide KSL-W were added to the cells. Each concentration was tested in  
49 duplicate. The cells were incubated at 37°C in a 5% CO<sub>2</sub> atmosphere for 6 and 24 h and subjected  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 thereafter to Hoechst staining. The cells were then fixed with methanol (Fisher Scientific Co.,  
4 Ottawa, ON, Canada) and glacial acetic acid (Merck KGaA) (75/25, v/v) for  $3 \times 15$  min, and  
5  
6 subsequently washed 3 times with phosphate-buffered saline (PBS). Thereafter, the cells were  
7  
8 incubated with Hoechst 33342 (H42) (Riedel de Haen, Seele, Germany) ( $1 \mu\text{g}/\text{mL}$ ) in PBS for  
9  
10 15 min at room temperature in the dark. After three washes with deionized water, the samples  
11  
12 were observed and photographed using an epifluorescence light microscope (Axiophot, Zeiss,  
13  
14 Oberkochen, Germany). At least 10 fields from each slide were photographed and used to count  
15  
16 the stained cells in each field. Results are reported as the means  $\pm$  SD of four separate  
17  
18 experiments.  
19  
20  
21  
22  
23  
24  
25  
26

### 27 **Effect of peptide KSL-W on primary human gingival fibroblast growth**

28  
29 Primary human gingival fibroblasts were seeded into 6-well plates ( $10^4$  cells/well) in DME  
30  
31 medium supplemented with 10% FBS. The cells were then incubated in a 5%  $\text{CO}_2$  humid  
32  
33 atmosphere at  $37^\circ\text{C}$  for 24 h, after which time the culture medium was refreshed and the cells  
34  
35 were treated with 0, 10, 50, or  $100 \mu\text{g}/\text{mL}$  of peptide KSL-W. Each concentration was tested in  
36  
37 duplicate. The cells were maintained for 3 and 6 days, and the medium was changed every 48 h.  
38  
39 At the end of the incubation, the cells were detached from the culture plates with 0.05%  
40  
41 trypsin/0.01 EDTA solution and subsequently washed twice with culture medium, with the viable  
42  
43 cell numbers assessed by Trypan blue exclusion assay (Gilbert *et al.*, 2005). Briefly,  $100 \mu\text{l}$  from  
44  
45 each cell suspension were mixed with the same volume of Trypan blue (Sigma-Aldrich) solution  
46  
47 (0.4%) and incubated 5 min on ice. Viable cells were determined in triplicate for each suspension  
48  
49 by means of an inverted optical microscope to count the Trypan blue-free cells. Results are  
50  
51 reported as the means  $\pm$  SD of five different experiments.  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Effect of KSL-W on primary human gingival fibroblast cell cycle

Primary human gingival fibroblasts were seeded into 6-well plates at  $10^4$  cells/well and incubated for 48 h in a 5% CO<sub>2</sub> humid atmosphere at 37°C, after which time the medium was refreshed, and the cells were treated with peptide KSL-W at concentrations of 0, 10, 50, or 100 µg/mL; two wells per condition. The cells were maintained in culture for 24 h, then detached from the culture plates as described above, washed twice with PBS, and subsequently used for cell cycle analysis. Briefly, the cells were suspended in RNase (Promega, Madison, WI, USA) (10 mg/mL) solution and incubated at 37°C for 1 h, after which time propidium iodide (PI) (Abcam Inc., Toronto, ON, Canada) (50 mg/mL) was added to each cell suspension prior to analysis. The percentage of cells in the G1, S, and G2/M phases of the cell cycle were analyzed using an Epics<sup>®</sup> Elite ESP flow cytometer (Beckman Coulter, Miami, FL, USA). The single cell population was gated using pulse width vs. pulse area to exclude clumps and doublets and the scatter plot was used to exclude any obvious debris. The PI was detected using an FL4 channel vs. a cell count histogram plot. Results are reported as the means ± SD of three different experiments.

### Cell Migration/Monolayer Wound Repair Assay

*In vitro* wound repair assays were performed as previously described (Semlali *et al.*, 2011). Briefly, primary human gingival fibroblasts were seeded ( $2 \times 10^5$ /well) into 6-well plates and grown to confluence. A scratch wound was then created on each confluent monolayer by means of a 200 µL sterile pipette tip (PipetTipFinder, Lab Procurement Services, LLC, Knoxville, TN, USA) perpendicular to the bottom of the dish. This generated a wound approximately 0.44 to 0.50 mm in width. The culture medium was refreshed with new medium, supplemented or not

1  
2  
3 peptide KSL-W at 10, 50, or 100  $\mu\text{g}/\text{mL}$ , and incubated at  $37^\circ\text{C}$  in a  $\text{CO}_2$  humid atmosphere. At  
4  
5 the end of each incubation period (0, 12, 24, and 48 h), the cells were fixed with 4%  
6  
7 paraformaldehyde solution (Alfa Aesar, Ward Hill, MA, USA) for 60 min at  $4^\circ\text{C}$ , washed twice  
8  
9 with PBS, and subjected thereafter to crystal violet staining (Sigma-Aldrich). One milliliter of  
10  
11 1% w/v crystal violet solution in demineralized water was added to each well and the cultures  
12  
13 were then incubated at room temperature for 15 min, after which time the non-bound dye was  
14  
15 removed from the wells by thorough washing with demineralized water, followed by drying at  
16  
17  $37^\circ\text{C}$ . Digital photographs of each wound were taken (Coolpix 950, Nikon Canada, Montréal,  
18  
19 QC, Canada) at various time points following the creation of the wound. Wound closure (cell  
20  
21 migration) was investigated using the NIH Image J public domain image processing program to  
22  
23 measure the distance between the opposite edges of the wound as a function of time. Data  
24  
25 (means  $\pm$  SD,  $n = 5$ ) were collected and presented as the percentage of initial wound (distance at  
26  
27 time zero) using the following formula: ((distance at initial scratch – distance after an identified  
28  
29 culture period)  $\div$  (distance at initial scratch))  $\times 100\%$ . The KSL-W-treated and untreated cell  
30  
31 cultures were compared, with the difference considered significant at  $p < 0.05$ .  
32  
33  
34  
35  
36  
37  
38  
39  
40

#### 41 **Effect of peptide KSL-W on MMP-1, MMP-2, TIMP-1, and TIMP-2 secretion by** 42 **primary human gingival fibroblasts** 43 44

45  
46 Spent culture media were collected to determine MMP-1, MMP-2, TIMP-1 and TIMP-2 protein  
47  
48 levels. These were obtained from primary human gingival fibroblasts at  $2 \times 10^5/\text{well}$  in 6-well  
49  
50 plates treated with peptide KSL-W at 0, 10, 50, or  $100 \mu\text{g}/\text{mL}$ , in duplicate, for 3 and 6 days.  
51  
52 They were analyzed thereafter by sandwich enzyme-linked immunosorbent assays (ELISA, R&D  
53  
54 Systems, Minneapolis, MN, USA). Briefly, the cell culture media were collected in tubes  
55  
56  
57  
58  
59  
60

1  
2  
3 containing 1  $\mu$ L of a protease inhibitor cocktail (Sigma-Aldrich) for specific use with mammalian  
4 cell and tissue extracts. The culture media were then filtered through 0.22  $\mu$ m filters and used to  
5 quantify MMP-1, MMP-2, TIMP-1, and TIMP-2 concentrations, according to the manufacturer's  
6 instructions. The plates were read at 450 nm and analyzed by means of a Model 680 Microplate  
7 Reader (Bio-Rad, Hercules, CA, USA). According to the manufacturer, the minimum detectable  
8 concentrations were under 1 pg/mL for MMP-1, 0.7 pg/mL for MMP-2, 3.5 pg/mL for TIMP-1,  
9 and 3.5 pg/mL for TIMP-2. Each experiment was repeated four times and the means  $\pm$  SD were  
10 calculated and presented.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

25 **Effect of peptide KSL-W on primary human gingival fibroblast interaction with**  
26 ***S. mutans***  
27  
28

29 To investigate the effect of peptide KSL-W on *Streptococcus mutans*-infected primary human  
30 gingival fibroblasts, cells were seeded into 6-well plates at  $10^4$  cells/well and incubated thereafter  
31 in a 5% CO<sub>2</sub> humid atmosphere at 37°C for 4 days. The medium was then refreshed and treated  
32 with or without peptide KSL-W at 10, 50, or 100  $\mu$ g/mL; two wells per condition. An *S. mutans*  
33 suspension (100  $\mu$ L) at  $1 \times 10^8$  CFU/mL was then immediately used to infect the gingival  
34 fibroblast monolayer cultures. As a negative control, fibroblast cultures without KSL-W were  
35 also infected with 100  $\mu$ L of *S. mutans* suspension. As a positive control, fibroblast cultures  
36 infected with 100  $\mu$ L of *S. mutans* suspension were immediately supplemented with an antibiotic  
37 cocktail (penicillin (30 mg/mL)/streptomycin (50 mg/mL)) (Gibco-Thermo Fisher Scientific,  
38 Gaithersburg, MD, USA) to prevent bacterial growth. Following infection with *S. mutans*, the  
39 cell cultures were maintained in a 5% CO<sub>2</sub> humid atmosphere at 37°C for 6 h, after which time  
40 the culture medium from each condition was collected, filtered by 0.22  $\mu$ m filters, and used to  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 quantify IL-8 concentrations using an ELISA kit (R&D Systems). The plates were read at 450 nm  
4  
5 and analyzed by means of a Model 680 Microplate Reader (Bio-Rad). According to the  
6  
7 manufacturer, the minimum detectable concentration of IL-8 was between 1.5 and 7.5 pg/mL.  
8  
9 The experiment was repeated three times and the means  $\pm$  SD were calculated and presented.  
10  
11 Following treatment with KSL-W in the presence or absence of *S. mutans*, adherent cells were  
12  
13 washed twice with PBS, fixed with 4% paraformaldehyde for 60 min, and stained thereafter with  
14  
15 crystal violet, as described above. The stained cells were then observed under an inverted  
16  
17 microscope and photographed. At least 10 fields from each slide were photographed and  
18  
19 subsequently used to count the stained cells in each field. Results are reported as the means  $\pm$  SD  
20  
21 of four separate experiments (n = 4).  
22  
23  
24  
25  
26  
27  
28

## 29 Results

### 30 Peptide KSL-W promoted primary human gingival fibroblast adhesion and growth

31  
32 Primary human gingival fibroblasts were treated with various concentrations of peptide KSL-W  
33  
34 and analyzed to determine the effect of this antimicrobial peptide on their attachment and  
35  
36 morphology. As shown in **Fig. 1A**, peptide KSL-W had no adverse effect on cell morphology and  
37  
38 adhesion following incubation for 6 and 24 h. The cells were well distributed over the plate,  
39  
40 similar to that observed with the untreated control cells. Optical microscope observations showed  
41  
42 elongated fibroblasts with a dense nucleus and a small amount of cytoplasm (**Fig. 1A**).  
43  
44 Quantitative evaluation (numbering) of the adherent cells (**Fig. 1B**) confirmed that peptide KSL-  
45  
46 W did not reduce/inhibit primary human gingival fibroblast adhesion. The numbers of adherent  
47  
48 cells in the presence of peptide KSL-W were comparable to those found in the control, and even  
49  
50 greater at 6 and 24 h.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Cell growth analyses confirm these data. As shown in **Fig. 2**, compared to the non-KSL-W-  
4 stimulated primary human gingival fibroblast culture, a trend showing a slight increase of viable  
5 primary human gingival fibroblasts was observed at 3 days, although this was not statistically  
6 significant. However, at 6 days, compared to the control, the KSL-W-treated cultures recorded  
7 higher viable cell numbers, which was statistically significant. KSL-W was able to cause an  
8 increase in the number of viable primary human gingival fibroblasts at as low as 10 µg/mL. This  
9 increase was not only maintained but showed a trend of further increases in the presence of 50 or  
10 100 µg/ml of the peptide, although this increase was not statistically significant. Overall results  
11 demonstrate that peptide KSL-W promoted primary human gingival fibroblast adhesion and  
12 growth.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

### 30 **Peptide KSL-W promoted human gingival fibroblast cell cycle**

31  
32 The KSL-W-induced cell growth increase possibly occurred through a promotion of the cell cycle  
33 progression. To monitor the effect of peptide KSL-W on the cell cycle, gingival fibroblasts were  
34 treated with various concentrations of KSL-W for 24 or 48 h, after which time the cell  
35 percentages were quantified in different cell cycle phases (**Fig. 3**). Quantitatively, in the KSL-W-  
36 untreated group at 24 h post-culture, approximately 70% of the cells were in the G<sub>0</sub>/G<sub>1</sub> phase,  
37 while over 7% of the cells were in the S phase, and close to 14% were in the G<sub>2</sub>/M phase (**Fig. 3**).  
38 However, following exposure to KSL-W, the G<sub>0</sub>/G<sub>1</sub> phase values significantly ( $p < 0.05$ )  
39 decreased, and specifically with 50 and 100 µg/mL of the peptide. In contrast, the S and G<sub>2</sub>/M  
40 phase values significantly ( $p < 0.05$ ) increased when peptide KSL-W was introduced at  
41 100 µg/mL. Similar results were obtained with fibroblasts stimulated with KSL-W for 48 h  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Peptide KSL-W increased MMP-1, MMP-2, TIMP-1, and TIMP-2 secretion by human gingival fibroblasts

Protein analyses of the spent culture media reveal that peptide KSL-W modulated the levels of remodeling enzyme proteins MMP-1 and MMP-2 secreted by the gingival fibroblasts (**Fig. 4**). The effects were observed after 3 and 6 days of peptide treatment, compared to untreated cultures. At 3 days post-KSL-W treatment, significant ( $p < 0.05$ ) increases in MMP-1 levels were observed with 50 and 100  $\mu\text{g}/\text{mL}$  of the peptide, compared to the untreated cells. Similar observations were made for the 6-day fibroblast culture in the presence of 50 and 100  $\mu\text{g}/\text{mL}$  of KSL-W. The levels of secreted MMP-1 were greater at 6 days than at 3 days, regardless of the test conditions (control or KSL-W-treated cultures). Comparable data were obtained by MMP-2. **Fig. 4** shows significantly higher ( $p < 0.05$ ) MMP-2 protein levels with 50 and 100  $\mu\text{g}/\text{mL}$  of peptide KSL-W, at both 3 and 6 days post-stimulation.

Because peptide KSL-W increased MMP-1 and MMP-2 secretion, we also investigated TIMP-1 and TIMP2, as they are involved in regulating MMP activities. **Fig. 5** shows that peptide KSL-W increased TIMP-1 secretion by the primary gingival fibroblasts. This increase was statistically significant ( $p < 0.05$ ) in the presence of both 50 and 100  $\mu\text{g}/\text{mL}$  of KSL-W and at both 3 and 6 days of stimulation with the peptide. A comparable increasing trend was observed for TIMP-2 (**Fig. 5**). Indeed, at 3 days, a significant increase in TIMP-2 secretion was observed in the presence of 50 and 100  $\mu\text{g}/\text{mL}$  of peptide KSL-W, and at 6 days, TIMP-2 secretion showed an increased trend at all three concentrations of KSL-W tested. Overall data thus confirm the upregulation of MMP-1 and MMP-2 by peptide KSL-W. The increase of these proteolytic enzymes was paralleled with an increase of protease inhibitors (TIMP-1 and TIMP-2).



### Peptide KSL-W promoted cell migration and wound closure

Because peptide KSL-W was found to promote fibroblast adhesion and growth, we investigated its ability to promote fibroblast migration. This was determined by a scratch wound closure experiment. Wounds were created in gingival fibroblast monolayers and cell migration from the edge of the scratch toward the center (wound closure) was recorded at different times post-wounding. The fibroblasts treated with peptide KSL-W actively migrated from both edges and closed the entire wound at 48 h (**Fig. 6**). This healing rate was much more rapid than that of the untreated cells which showed 25 to 30% of the wound to be unhealed at 48 h (**Fig. 6**). Further quantitative analysis revealed that compared to the untreated controls, a significant ( $p < 0.05$ ) reduction of wound distance at 12 and 24 h was observed for the cells treated with 50 and 100  $\mu\text{g/ml}$  of peptide KSL-W (**Fig. 6**). It appears that the higher the peptide concentration, the greater the migration rate.

### Peptide KSL-W prevented the adverse effect of *S. mutans* on fibroblast growth and IL-8 secretion

Following seeding, 4-day-old fibroblast cultures were infected with *S. mutans* in the presence or absence of peptide KSL-W. **Fig. 7A** shows that in the absence of the peptide, a low cell distribution was observed throughout the culture surface. The addition of peptide KSL-W at 50 and 100  $\mu\text{g/mL}$  reduced the adverse effect caused by *S. mutans*, resulting in maintaining a higher number of adherent cells on the culture plate. To quantitatively confirm this observation, cell lysis was performed following crystal violet staining and measurement of its absorbance. As shown in **Fig. 7B**, the KSL-W-supplemented fibroblast culture showed an absorbance level comparable to that obtained by the non-infected culture or the antibiotic-supplemented *S. mutans*-

1  
2  
3 infected fibroblast culture, suggesting that peptide KSL-W played a preventive role against  
4  
5 *S. mutans* infection.  
6

7  
8 To support this observation, IL-8 secretion was also measured. **Fig. 8** shows that the non-  
9  
10 stimulated, non-infected fibroblasts secreted a basal level of IL-8 (approximately 700 pg/mL).  
11  
12 Following infection with *S. mutans*, the level of IL-8 increased to 1000 pg/mL. The killing of  
13  
14 *S. mutans* by the antibiotics led to a decrease in IL-8 secretion, compared to that recorded by the  
15  
16 infected cultures. Interestingly, the addition of 50 and 100 µg/mL of peptide KSL-W resulted in  
17  
18 reduced levels of IL-8 secretion, ranging from over 900 pg/mL with 50 µg/ml of KSL-W to less  
19  
20 than 750 pg/mL with 100 µg/mL of the peptide. Overall data show that peptide KSL-W  
21  
22 decreased the adverse effect of *S. mutans* on gingival fibroblast growth and reduced the  
23  
24 inflammatory response against the bacteria by decreasing IL-8 secretion.  
25  
26  
27  
28  
29  
30  
31

## 32 **Discussion**

33  
34 Various antimicrobial peptides have been shown to display *in vitro* activity against a wide range  
35  
36 of bacterial pathogens and are thus being proposed as additional alternatives to develop novel  
37  
38 antibacterial disease-control strategies (Martin *et al.*, 2015; Yu *et al.*, 2016). Among available  
39  
40 antimicrobial peptides, peptide KSL-W demonstrated improved stability in simulated oral  
41  
42 conditions with broad spectrum antimicrobial activity (Na *et al.*, 2005). Furthermore, combined  
43  
44 with sub-inhibitory concentrations of benzalkonium chloride, a known cationic surface-active  
45  
46 agent (Baker *et al.*, 1978), peptide KSL-W was shown to significantly reduce oral biofilm growth  
47  
48 *in vitro* (Bernegossi *et al.*, 2015).  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 In addition to the inherent ability of antimicrobial peptide to kill bacteria, some of these peptides,  
4 such as LL37, have demonstrated wound healing properties (Grönberg *et al.*, 2014). We therefore  
5 sought to study the effect of peptide KSL-W on primary human gingival fibroblasts when used  
6 orally to control oral biofilm growth. Our results indicate that this antimicrobial peptide was  
7 indeed non-toxic. Indeed, even at a high concentration (100 µg/mL), peptide KSL-W did not  
8 reduce cell adhesion or growth. We also found that peptide KSL-W, similar to other antimicrobial  
9 peptides, could be beneficial to human cells. We previously demonstrated that nisin Z, an  
10 antimicrobial peptide produced by *Lactococcus lactis subsp.*, significantly reduced fibroblast  
11 growth and differentiation (Akerey *et al.*, 2009), demonstrating the capacity of nisin Z to promote  
12 cell growth under infected conditions. Similar beneficial effects of peptide KSL-W were  
13 observed with Hacat cells and human dermal fibroblasts (Kosikowska *et al.*, 2015). Furthermore,  
14 ocellatin peptides extracted from frog *Leptodactylus pustulatus* skin showed microbial growth  
15 control with no adverse effect on human erythrocytes and a murine fibroblast cell line (Marani *et*  
16 *al.*, 2015).  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

39 In our study, the effect of peptide KSL-W on fibroblast growth appears to have occurred through  
40 its influence on the cell cycle, as the KSL-W-treated cell cultures recorded a greater number of  
41 cells at the S and G2/M phases. These data provide insight on certain factors contributing to the  
42 increased fibroblast growth observed on the KSL-W-treated gingival fibroblasts. This effect is  
43 comparable to the naturally occurring peptide catestatin secreted by human keratinocytes. Hoq *et*  
44 *al.* (2011) showed that in addition to inhibiting the growth of pathogens, catestatin peptides  
45 promoted keratinocyte proliferation (Hoq *et al.*, 2011). Because fibroblasts adhered and  
46 proliferated in the presence of KSL-W, this may have increased their physiological activity by  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 stimulating MMP secretion and that of their inhibitors (TIMPs). Indeed, our results reveal  
4 increased levels of MMP-1, MMP-2, TIMP-1, and TIMP-2 secretion by gingival fibroblasts  
5  
6 when they were exposed to peptide KSL-W.  
7  
8  
9

10  
11  
12 Similar to what was reported with  $\beta$ -defensin-3 (Nishimura *et al.*, 2004), the increased secretion  
13 of MMP-1 and MMP-2 by the KSL-W-stimulated fibroblasts may suggest a role of peptide KSL-  
14  
15 W in mediating part of the tissue remodeling processes. Alternatively, changes in MMPs could be  
16  
17 considered as an inflammatory response by the fibroblasts to the presence of peptide KSL-W, as  
18  
19 previously demonstrated (Nishimura *et al.*, 2004) with other antimicrobial peptides, such as  
20  
21 human  $\beta$ -defensin-3 which was shown to cause an increase in prostaglandin-(PGE)<sub>2</sub> and MMP-1  
22  
23 secretion levels by human gingival fibroblasts. Similar observations were reported with  $\alpha$ -  
24  
25 defensin-1, which caused increased levels of mRNA expression of IL-6, IL-8, MMP-1, and  
26  
27 MMP-3 by fibroblast-like synoviocytes (Ahn *et al.*, 2013). In our study, when gingival  
28  
29 fibroblasts were exposed to peptide KSL-W, the increased MMP secretion was paralleled by  
30  
31 TIMP-1 and TIMP-2 secretion. This is the first study to report an increase in TIMP1 and TIMP-2  
32  
33 secretion by KSL-W-stimulated fibroblasts. Overall, peptide KSL-W treatment stimulated  
34  
35 fibroblast growth and increased MMP and TIMP secretion, which suggests that this peptide may  
36  
37 play a role in cell migration and wound healing.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 To test this hypothesis, KSL-W-stimulated gingival fibroblasts were subjected to an *in vitro*  
49  
50 wound scratch assay which showed that peptide KSL-W at 50 and 100  $\mu$ g/ml promoted fibroblast  
51  
52 migration and wound closure. These findings are in agreement with those of earlier studies  
53  
54 showing that human  $\beta$ -defensin-2 increased keratinocyte cytokine production and migration  
55  
56  
57  
58  
59  
60

1  
2  
3 (Niyonsaba *et al.*, 2007). Human  $\beta$ -defensin-3 was also shown to be highly expressed by  
4  
5  
6 keratinocytes at wound sites to promote cell migration and proliferation (Niyonsaba *et al.*, 2007;  
7  
8 Sørensen *et al.*, 2005; Niyonsaba *et al.*, 2005) and to significantly accelerate wound closure  
9  
10 when topically applied in a porcine model of infected skin wounds (Hirsch *et al.*, 2009). Overall  
11  
12 data demonstrate that synthetic peptide KSL-W not only exhibited wound healing properties but  
13  
14 played an active role in promoting wound healing, which supports previously reported results  
15  
16 with naturally occurring  $\beta$ -defensin peptides. However, the wound healing activity demonstrated  
17  
18 by peptide KSL-W will require further investigation using clinically relevant animal wound  
19  
20 healing models.  
21  
22  
23  
24  
25  
26

27 Our results show that peptide KSL-W, similar to the test antibiotic, was able to mitigate the  
28  
29 adverse effect of *S. mutans* on cell density in gingival fibroblasts. These findings confirm  
30  
31 previous results showing peptide KSL-W to display both bactericidal (Dixon *et al.*, 2008) and  
32  
33 anti-fungal (Theberge *et al.*, 2013) properties. Furthermore, peptide KSL-W controlled the  
34  
35 inflammatory response following *S. mutans* infection. The effect of peptide KSL-W on  
36  
37 controlling IL-8 secretion following bacterial infection was comparable to that observed with the  
38  
39 antibiotic. These results suggest that peptide KSL-W may indirectly help fibroblasts to sense  
40  
41 bacterial presence, thus secreting IL-8 when needed. Further studies will shed light on the  
42  
43 signaling pathways involved in such controls. Our overall findings thus confirm that  
44  
45 antimicrobial peptide KSL-W is non-toxic, has the ability to control infection, and may possess  
46  
47 wound healing properties.  
48  
49  
50  
51  
52  
53  
54

#### 55 **Authors' contributions**

56  
57  
58  
59  
60

1  
2  
3 MR and KPL and AS designed the experiments, supervised the research and wrote the paper.  
4  
5 HJP, MS, AS and MR performed the experiments and data analyses and contributed to the  
6  
7 writing of the paper. Each author read and approved the final manuscript.  
8  
9

### 10 11 **Funding**

12  
13  
14 This study was supported financially by the United States Army Medical Research and Materiel  
15  
16 Command (Award number ERMS No. 12304006) and by a grant from the Fonds Émile-Beaulieu,  
17  
18 at Université Laval foundation.  
19  
20

### 21 22 23 **DOD Disclaimer**

24  
25  
26 One of the authors (KPL) is a United States Government employee. The work presented is part of  
27  
28 his official duties. The opinions or assertions contained herein are the personal views of these  
29  
30 authors and are not to be construed as official or reflecting the views of the United States Army  
31  
32 or Department of Defense.  
33  
34  
35  
36  
37

### 38 39 **Conflict of Interest**

40 None declared  
41  
42

### 43 44 **Ethical approval**

45  
46 Not required.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

- Ahn, J.K., Huang, B., Bae, E.K., Park, E.J., Hwang, J.W., Lee, J., Koh, E.M. and Cha, H.S. (2013) The role of  $\alpha$ -defensin-1 and related signal transduction mechanisms in the production of IL-6, IL-8 and MMPs in rheumatoid fibroblast-like synoviocytes. *Rheumatology (Oxford)* **52**,1368–76.
- Akerey, B., Le-Lay, C., Fliss, I., Subirade, M. and Rouabhia, M. (2009) In vitro efficacy of nisin\_Z against *Candida albicans* adhesion and transition following contact with normal human gingival cells. *J Appl Microbiol* **107**, 1298–307.
- Al-Ahmad, A., Roth, D., Wolkewitz, M., Wiedmann-Al-Ahmad, M., Follo, M., Ratka-Krüger, P., Deimling, D., Hellwig, E. *et al.* (2010) Change in diet and oral hygiene over an 8-week period: effects on oral health and oral biofilm. *Clin Oral Investig* **14**, 391–6.
- Andrian, E., Grenier, D. and Rouabhia, M. (2005) *Porphyromonas gingivalis* lipopolysaccharide induces shedding of syndecan-1 expressed by gingival epithelial cells. *J Cell Physiol* **204**, 178–83.
- Andrian, E., Mostefaoui, Y., Rouabhia, M. and Grenier, D. (2007) Regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by *Porphyromonas gingivalis* in an engineered human oral mucosa model. *J Cell Physiol* **211**, 56–62.
- Baker, P.J., Coburn, R.A., Genco, R.J. and Evans, R.T. (1978) The in vitro inhibition of microbial growth and plaque formation by surfactant drugs. *J Periodontal Res* **13**, 474–85.
- Barrientos, S., Stojadinovic, O., Golinko, M.S., Brem, H. and Tomic-Canic, M. (2008) Growth factors and cytokines in wound healing. *Wound Repair Regen* **16**, 585–601.
- Bernegossi, J., Calixto, G.M., Sanches, P.R., Fontana, C.R., Cilli, E.M., Garrido, S.S. and Chorilli, M. (2015) Peptide\_KSL-W-Loaded Mucoadhesive Liquid Crystalline Vehicle as an Alternative Treatment for Multispecies Oral Biofilm. *Molecules* **21**, 14.
- Cavalcanti, I.M., Nobbs, A.H., Ricomini-Filho, A.P., Jenkinson, H.F. and Cury, A.A. (2016) Interkingdom cooperation between *Candida albicans*, *Streptococcus oralis* and *Actinomyces oris* modulates early biofilm development on denture material. *Pathog Dis* Jan 10; pii:ftw002.
- Chen, Y., Zhao, H., Zhang, X., Luo, H., Xue, X., Li, Z. and Yao, B. (2013) Identification, expression and bioactivity of *Paramisgurnus dabryanus*  $\beta$ -defensin that might be involved in immune defense against bacterial infection. *Fish Shellfish Immunol* **35**, 399–406.
- Derradjia, A., Alanazi, H., Park, H.J., Djeribi, R., Semlali, A. and Rouabhia, M. (2015)  $\alpha$ -tocopherol decreases interleukin-1 $\beta$  and -6 and increases human  $\beta$ -defensin-1 and -2 secretion in human gingival fibroblasts stimulated with *Porphyromonas gingivalis* lipopolysaccharide. *J Periodontal Res* Jul 27. doi: 10.1111/jre.12308.
- Dewhirst, F.E., Chen, T., Izard, J., Paster, B.J., Tanner, A.C.R., Yu, W.H., Lakshmanan, A. and Wade, W.G. (2010) The human oral microbiome. *J Bacteriol* **192**, 5002–17.
- Dixon, D.R., Karimi-Naser, L., Darveau, R.P. and Leung, K.P. (2008) The anti-endotoxic effects of the KSL-W decapeptide on *Escherichia coli* O55:B5 and various oral lipopolysaccharides. *J Periodontal Res* **43**, 422–30.
- Fernandes, P. (2006) Antibacterial discovery and development - the failure of success? *Nat Biotechnol* **24**, 1497–503.
- Fernández, C.E., Giacaman, R.A., Tenuta, L.M. and Cury, J.A. (2015) Effect of the Probiotic *Lactobacillus rhamnosus* LB21 on the Cariogenicity of *Streptococcus mutans* UA159 in a Dual-Species Biofilm Model. *Caries Res* **49**, 583–90.

- 1  
2  
3 Gilbert, V., Rouabhia, M., Wang, H., Arnould, A.L., Remondetto, G. and Subirade, M. (2005)  
4 Characterization and evaluation of whey protein-based biofilms as substrates for in vitro cell  
5 cultures. *Biomaterials* **26**, 7471–80.
- 6  
7 Grönberg, A., Mahlapuu, M., Ståhle, M., Whately-Smith, C. and Rollman, O. (2014) Treatment  
8 with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a  
9 randomized, placebo-controlled clinical trial. *Wound Repair Regen* **22**, 613-21.
- 10 Guo, M., Wei, J., Huang, X., Huang, Y. and Qin, Q. (2012) Antiviral effects of beta-defensin  
11 derived from orange-spotted grouper (*Epinephelus coioides*). *Fish Shellfish Immunol* **32**,  
12 828–38.
- 13  
14 Hajishengallis, E., Parsaei, Y., Klein, M.I. and Koo, H. (2015) Advances in the microbial  
15 etiology and pathogenesis of early childhood caries. *Mol Oral Microbiol* Dec 30;doi:  
16 10.1111/omi.
- 17  
18 Hirsch, T., Spielmann, M., Zuhaili, B., Fossum, M., Metzger, M., Koehler, T., Steinau, H.U., Yao,  
19 F. *et al.* (2009) Human beta-defensin-3 promotes wound healing in infected diabetic wounds.  
20 *J Gene Med* **11**, 220–8.
- 21  
22 Hong, S.Y., Oh, J.E., Kwon, M., Choi, M.J., Lee, J.H., Lee, B.L., Moon, H.M. and Lee, K.H.  
23 (1998) Identification and characterization of novel antimicrobial decapeptides generated by  
24 combinatorial chemistry. *Antimicrob Agents Chemother* **42**, 2534–41.
- 25  
26 Hoq, M.I., Niyonsaba, F., Ushio, H., Aung, G., Okumura, K. and Ogawa, H. (2011) Human  
27 catestatin enhances migration and proliferation of normal human epidermal keratinocytes. *J*  
28 *Dermatol Sci* **64**, 108–18.
- 29  
30 Horz, H-P. and Conrads, G. (2007) Diagnosis and anti-infective therapy of periodontitis. *Expert*  
31 *Rev Anti infect Ther* **5**, 11.
- 32  
33 Nishimura, M., Abiko, Y., Kurashige, Y., Takeshima, M., Yamazaki, M., Kusano, K., Saitoh, M.,  
34 Nakashima, K. *et al.* (2004) Effect of defensin peptides on eukaryotic cells: primary  
35 epithelial cells, fibroblasts and squamous cell carcinoma cell lines. *J Dermatol Sci* **36**, 87-95.
- 36  
37 Johansson, I., Witkowska, E., Kaveh, B., Lif Holgersson, P. and Tanner, A.C. (2016) The  
38 Microbiome in Populations with a Low and High Prevalence of Caries. *J Dent Res* **95**, 80–6.
- 39  
40 Kanangat, S., Postlethwaite, A., Hasty, K., Kang, A., Smeltzer, M., Appling, W. and Schaberg,  
41 D. (2006) Induction of multiple matrix metalloproteinases in human dermal and synovial  
42 fibroblasts by *Staphylococcus aureus*: implications in the pathogenesis of septic arthritis and  
43 other soft tissue infections. *Arthritis Res Ther* **8**, R176.
- 44  
45 Kosikowska, P., Pikula, M., Langa, P., Trzonkowski, P., Obuchowski, M. and Lesner, A. (2015)  
46 Synthesis and Evaluation of Biological Activity of Antimicrobial--Pro-Proliferative Peptide  
47 Conjugates. *PLoS One* **10**, e0140377.
- 48  
49 Leung, K.P., Crowe, T.D., Abercrombie, J.J., Molina, C.M., Bradshaw, C.J., Jensen, C.L., Luo,  
50 Q. and Thompson, G.A. (2005) Control of oral biofilm formation by an antimicrobial  
51 decapeptide. *J Dent Res* **84**, 1172–7.
- 52  
53 Levón, J., Al-Samadi, A., Mackiewicz, Z., Coer, A., Trebse, R., Waris, E. and Konttinen, Y.T.  
54 (2015) Human beta-defensin-3 producing cells in septic implant loosening. *J Mater Sci*  
55 *Mater Med* **26**, 98.
- 56  
57 Ling, Z., Kong, J., Jia, P., Wei, C., Wang, Y., Pan, Z., Huang, W., Li, L. *et al.* (2010) Analysis of  
58 oral microbiota in children with dental caries by PCR-DGGE and barcoded pyrosequencing.  
59 *Microb Ecol* **60**, 677–90.
- 60  
61 Mahanonda, R., Sa-Ard-Iam, N., Eksomtramate, M., Rerkyen, P., Phairat, B., Schaecher, K.E.,  
62 Fukuda, M.M. and Pichyangkul, S. (2009) Cigarette smoke extract modulates human beta-



- 1  
2  
3 defensin-2 and interleukin-8 expression in human gingival epithelial cells. *J Periodontal Res*  
4 **44**, 557–64.
- 5  
6 Marani, M.M., Dourado, F.S., Quelemes, P.V., de Araujo, A.R., Perfeito, M.L., Barbosa, E.A.,  
7 Vêras, L.M., Coelho, A.L. *et al.* (2015) Characterization and Biological Activities of  
8 Ocellatin Peptides from the Skin Secretion of the Frog *Leptodactylus pustulatus*. *J Nat Prod*  
9 **78**, 1495–504.
- 10  
11 Martin, L., van Meegern, A., Doemming, S. and Schuerholz, T. (2015) Antimicrobial Peptides in  
12 Human Sepsis. *Front Immunol* **6**, 404.
- 13  
14 Mostefaoui, Y., Bart, C., Frenette, M. and Rouabhia, M. (2004) *Candida albicans* and  
15 *Streptococcus salivarius* modulate IL-6, IL-8, and TNF- $\alpha$  expression and secretion by  
16 engineered human oral mucosa cells. *Cell Microbiol* **6**, 1085–96.
- 17  
18 Na, D.H., Faraj, J., Capan, Y., Leung, K.P. and DeLuca, P.P. (2007) Stability of antimicrobial  
19 decapeptide (KSL) and its analogues for delivery in the oral cavity. *Pharm Res* **24**, 1544–50.
- 20  
21 Na, D.H., Faraj, J., Capan, Y., Leung, K.P. and DeLuca, P.P. (2005) Chewing gum of  
22 antimicrobial decapeptide (KSL) as a sustained antiplaque agent: preformulation study. *J*  
23 *Control Release* **107**, 122–30.
- 24  
25 Ng, H.M., Kin, L.X., Dashper, S.G., Slakeski, N., Butler, C.A. and Reynolds, E.C. (2015)  
26 Bacterial interactions in pathogenic subgingival plaque. *Microb Pathog* **15**, 00173–4.
- 27  
28 Nguyen, C.T., Park, S.S. and Rhee, D.K. (2015) Stress responses in *Streptococcus* species and  
29 their effects on the host. *J Microbiol* **53**, 741–9.
- 30  
31 Niyonsaba, F., Ushio, H., Nagaoka, I., Okumura, K. and Ogawa, H. (2005) The human beta-  
32 defensins (-1, -2, -3, -4) and cathelicidin LL-37 induce IL-18 secretion through p38 and ERK  
33 MAPK activation in primary human keratinocytes. *J Immunol* **175**, 1776–84.
- 34  
35 Niyonsaba, F., Ushio, H., Nakano, N., Ng, W., Sayama, K., Hashimoto, K., Nagaoka, I.,  
36 Okumura, K. *et al.* (2007) Antimicrobial peptides human beta-defensins stimulate epidermal  
37 keratinocyte migration, proliferation and production of proinflammatory cytokines and  
38 chemokines. *J Invest Dermatol* **127**, 594–604.
- 39  
40 Noronha, S.A., Noronha, S.M., Lanziani, L.E., Ipolito, M.Z., Ferreira, L.M. and Gragnani, A.  
41 (2014) Human beta defensin-4 and keratinocyte growth factor gene expression in cultured  
42 keratinocyte and fibroblasts of burned patients. *Acta Cir Bras* **29**, 39–43.
- 43  
44 Page-McCaw, A., Ewald, A.J. and Werb, Z. (2007) Matrix metalloproteinases and the regulation  
45 of tissue remodelling. *Nat Rev Mol Cell Biol* **8**, 221–33.
- 46  
47 Patil, S., Rao, R.S., Majumdar, B. and Anil, S. (2015) Clinical Appearance  
48 of Oral *Candida* Infection and Therapeutic Strategies. *Front Microbiol* **6**, 1391.
- 49  
50 Presland, R.B. and Dale, B.A. (2000) Epithelial structural proteins of the skin and oral cavity:  
51 function in health and disease. *Crit Rev Oral Biol Med* **11**, 383–408.
- 52  
53 Rouabhia, M., Schaller, M., Corbucci, C., Vecchiarelli, A., Prill, S.K., Giasson, L. and Ernst, J.F.  
54 (2005) Virulence of the fungal pathogen *Candida albicans* requires the five isoforms of  
55 protein mannosyltransferases. *Infect Immun* **73**, 4571–80.
- 56  
57 Semlali, A., Chakir, J. and Rouabhia, M. (2011) Effects of whole cigarette smoke on human  
58 gingival fibroblast adhesion, growth, and migration. *J Toxicol Environ Health A* **74**, 848–62.
- 59  
60 Semlali, A., Leung, K.P., Curt, S. and Rouabhia, M. (2011) Antimicrobial decapeptide KSL-W  
attenuates *Candida albicans* virulence by modulating its effects on Toll-like receptor, human  
 $\beta$ -defensin, and cytokine expression by engineered human oral mucosa. *Peptides* **32**, 859–67.
- Sonnenburg, J.L. and Fischbach, M.A. (2011) Community health care: therapeutic opportunities  
in the human microbiome. *Sci Transl Med* **3**, 1–5.

- 1  
2  
3 Sørensen, OE., Thapa, D.R., Rosenthal, A., Liu, L., Roberts, A.A. and Ganz, T. (2005)  
4 Differential regulation of beta-defensin expression in human skin by microbial stimuli. *J*  
5 *Immunol* **174**, 4870–9.  
6  
7 Theberge, S., Semlali, A., Alamri, A., Leung, K.P. and Rouabhia, M. (2013) *C. albicans* growth,  
8 transition, biofilm formation, and gene expression modulation by antimicrobial  
9 decapeptide\_KSL-W. *BMC Microbiol* **13**, 246.  
10  
11 Turnbaugh, P.J., Ley, R.E., Hamady, M., Fraser-Liggett, C.M., Knight, R. and Gordon, J.I.  
12 (2007) The human microbiome project: a strategy to understand the microbial components of  
13 the human genetic and metabolic landscape and how they contribute to normal physiology  
14 and predisposition to disease. *Nature* **449**, 804–10.  
15  
16 van Beurden, H.E., Von den Hoff, JW., Torensma, R., Maltha, J.C. and Kuijpers-Jagtman, A.M.  
17 (2005) Myofibroblasts in palatal wound healing: prospects for the reduction of wound  
18 contraction after cleft palate repair. *J Dent Res* **84**, 871–80.  
19  
20 Yu, G., D.Y., Regoes, R.R. and Rolff, J. (2016) The More The Better? Combination Effects  
21 of Antimicrobial Peptides. *Antimicrob Agents Chemother* Jan 4. pii: AAC.02434–15.  
22  
23 Zaura, E., Keijser, B.J., Huse, S.M. and Crielaard, W. (2009) Defining the healthy “core  
24 microbiome” of oral microbial communities. *BMC Microbiol* **9**, 259.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Figure Legends

**Fig. 1.** Peptide KSL-W enhanced the early adhesion of gingival fibroblasts. Cells were cultured with or without peptide KSL-W for 6 or 24 h and then stained with Hoechst. **(A)** Representative photos of adherent cells (*bar* 30  $\mu\text{m}$ ). **(B)** Count of adherent fibroblasts under the different conditions. Results are means + SD ( $n = 4$ ).

**Fig. 2.** Peptide KSL-W increased gingival fibroblast growth. Fibroblasts were treated with or without various concentrations of peptide KSL-W for 3 and 6 days. Viable cells were analyzed by Trypan blue exclusion assay. Numbers of live cells were plotted as mean + SD ( $n = 5$ ). P values were obtained by comparing the KSL-W-treated and untreated values.

**Fig. 3.** Peptide KSL-W promoted cell division. Following stimulation for 24 or 48 h, the cells were detached and used for cell cycle testing by PI staining. Quantitation of cell percentages at the different phases was determined by FAC analyses.  $P < 0.05$  was obtained by comparing the KSL-W-treated and untreated cells ( $n = 3$ ).

**Fig. 4.** Peptide KSL-W increased metalloproteinase (MMP-1 and MMP-2) secretion. Fibroblasts were stimulated for 3 and 6 days with different concentrations of peptide KSL-W. The cell supernatants were used to measure the MMPs using specific ELISA kits. Note the increased MMP levels with the high doses of peptide KSL-W at 3 and 6 days.  $P < 0.05$  was obtained by comparing the KSL-W-treated and untreated cells and the levels at 3 and 6 days ( $n = 4$ ).

**Fig. 5.** Peptide KSL-W enhanced metalloproteinase inhibitor (TIMP-1 and TIMP-2) secretion. Note the increased levels of TIMPs with the high doses of peptide KSL-W at 3 and 6 days.

1  
2  
3  $P < 0.05$  was obtained by comparing the KSL-W-treated and untreated cells and the levels at  
4  
5  
6 3 and 6 days ( $n = 4$ ).  
7  
8  
9

10 **Fig. 6.** Peptide KSL-W increased gingival fibroblast migration/repair. Cells were cultured up to  
11  
12 100% confluence. Scratches were then made on each monolayer and the medium was refreshed  
13  
14 and immediately treated with or without peptide KSL-W at different concentrations. The cultures  
15  
16 were maintained for various time periods prior to observation and determination of the wound  
17  
18 recovery. (A) Representative photos at 12 and 48 h post-wound (*bar* 50  $\mu\text{m}$ ). (B) Values are  
19  
20 means  $\pm$  SD ( $n = 5$ ). The KSL-W-treated and untreated cultures were compared, with the  
21  
22 difference considered significant at (\*)  $p < 0.05$ .  
23  
24  
25  
26  
27  
28  
29

30 **Fig. 7.** Peptide KSL-W reduced the adverse effect of *S. mutans* on gingival fibroblast  
31  
32 adhesion/density. At confluence, fibroblasts were pulsed with *S. mutans* in the presence or not of  
33  
34 peptide KSL-W. (A) Representative photos of adherent cells after 6 h of contact with *S. mutans*  
35  
36 in the presence or not of peptide KSL-W. (B) Density of live adherent cells assessed by crystal  
37  
38 violet staining were plotted as mean + SD ( $n = 4$ ). P values were obtained by comparing the  
39  
40 *S. mutans*-infected, KSL-W-treated, and untreated cultures.  
41  
42  
43  
44  
45  
46  
47

48 **Fig. 8.** Peptide KSL-W reduced the adverse effect of *S. mutans* on gingival fibroblast IL-8  
49  
50 secretion. IL-8 levels were obtained by ELISA measurement and were plotted as mean + SD  
51  
52 ( $n = 4$ ). P values were obtained by comparing the *S. mutans*-infected, KSL-W-treated, and  
53  
54 untreated cultures.  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58












Fig. 2



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58

After 24 h



After 48 h



KSL-W for 24 h

KSL-W for 48 h

Fig. 4





1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58






Fig. 6



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58






Fig. 8



## Appendix 1

### Le décapeptide KSL-W réduit la croissance de *Candida albicans* et dégrade les biofilms en diminuant l'expression de plusieurs gènes de virulence.

Theberge Simon<sup>1</sup>, Semlali Abdelhabib<sup>1,2</sup>, Alamri Abdullah<sup>1</sup>, Leung P. Kai<sup>3</sup>, and Rouabhia Mahmoud<sup>1</sup>

<sup>1</sup>Oral Ecology Research Group, Faculty of Dentistry, Laval University, Quebec, QC, Canada,

<sup>2</sup>Genome Research Chair, Department of Biochemistry, College of Science King Saud University, Riyadh, Kingdom of Saudi Arabia

<sup>3</sup>Dental and Trauma Research Detachment, US Army Institute of Surgical Research, Fort Sam Houston, TX, United States

**Introduction :** *Candida albicans* est le plus fréquent pathogène fongique impliqué dans les infections nosocomiales en Amérique du Nord<sup>1</sup>. Suivant l'utilisation courante d'antifongiques, *C. albicans* peut développer des résistances aux traitements conventionnels. Afin de pallier cet obstacle, le décapeptide KSL-W a été développé et présente un large spectre antimicrobien pouvant affecter *C. albicans*<sup>2,3</sup>.

**L'objectif** de cette étude est d'évaluer l'effet du KSL-W sur la croissance, la transformation de *C. albicans*, ainsi que sur l'expression des gènes impliqués dans la virulence de *C. albicans*.

**Matériels et Méthodes :** L'effet du KSL-W a été étudié en analysant la transformation de *C. albicans*-SC5314 en présence et en absence de KSL-W à l'aide de suivis microscopiques. Des analyses spécifiques au MTT et au XTT ont été réalisées afin de déterminer l'effet du KSL-W sur la prolifération ainsi que sur la formation et la dégradation de biofilm. Ces travaux ont été soutenus par l'analyse de l'expression des gènes *Sap2*, *Sap4*, *Sap5*, *Sap6*, *HWPI*, *EAP1*, *EFG1* et *NRG1* par la technique RT-qPCR. Tous les effets ont été comparés à l'amphotéricine B, un antifongique utilisé en clinique.

**Résultats et conclusions :** La transformation levure-hyphes est inhibée à partir de concentrations de 5 µg/ml. La prolifération est diminuée suivant une exposition de 5h à des concentrations de 10 µg/ml et persiste jusqu'à 10h avec des concentrations  $\geq 50$  µg/ml. La formation de biofilm est inhibée par des concentrations de  $\geq 25$  µg/ml. Les biofilms sont dégradés à partir de concentrations de 75 µg/ml. Le KSL-W réprime l'expression des gènes de virulence *Sap2*, *Sap4*, *Sap5*, *Sap6*, *HWPI*, *EAP1*. Les gènes *EFG1* et *NRG1* ont été régulés à la hausse par le KSL-W. Les effets sont comparables à l'amphotéricine B. Par ses effets sur les facteurs de virulence et par son effet sur les gènes de virulence, le KSL-W présente une alternative de traitement intéressante dans le contrôle des infections fongiques à *C. albicans* (This study was supported financially by the United States Army Medical Research and Materiel Command (Award number ERMS No. 12304006) and by a grant from the Fonds Émile-Beaulieu, a Université Laval foundation).

#### Références :

1. Wisplinghoff, H. et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America* **39**, 309–17 (2004).
2. Semlali, A. et al. Antimicrobial decapeptide KSL-W attenuates *Candida albicans* virulence by modulating its effects on Toll-like receptor, human  $\beta$ -defensin, and cytokine expression by engineered human oral mucosa. *Peptides* **32**, 859–67 (2011).
3. Leung, K.-P. et al. Control of Oral Biofilm Formation by an Antimicrobial Decapeptide. *Journal of Dental Research* **84**, 1172–1177 (2005).



## Appendix 2 :

Journée de la recherche faculté de médecine – 30 mai – soumission avant 4 avril

### **Un nouveau peptide antimicrobien contrôle la virulence de *Candida* en réduisant sa viabilité via un processus d'apoptose et de nécrose.**

THEBERGE SIMON<sup>1</sup>, Jacques Éric<sup>1</sup> and Leung Kai P<sup>2</sup> and Rouabhia Mahmoud<sup>1</sup>

<sup>1</sup> Groupe de recherche en écologie buccale, Université Laval

<sup>2</sup> Microbiology Branch, US Army Dental and Trauma Research Detachment, Institute of Surgical Research, Fort Sam Houston, TX, USA

**OBJECTIF** : Le décapeptide KSL-W présente un large spectre antimicrobien affectant plusieurs pathogènes dont *S. mutans* et *C. albicans*. Ce peptide semble réduire la croissance de *C. albicans* ainsi que la formation de biofilm en agissant sur certains gènes spécifiques. Cependant les mécanismes d'action du KSL-W ne sont pas encore élucidés. Dans cette étude, nous avons évalué la cinétique et l'atteinte de l'intégrité morphologique ainsi que le type de mort cellulaire (apoptotique/nécrotique) induites par le KSL-W sur *C. albicans* en comparaison à une autre souche soit : *C. parapsilosis*.

**MÉTHODES** : Les souches de *Candida* ont été mises en culture en présence et en absence de KSL-W. l'effet de KSL-W sur la viabilité cellulaire a été déterminé à l'aide du test d'exclusion du bleu trypan. Ces travaux ont été confirmés par des analyses de l'activité apoptotique ou nécrotique du KSL-W par cytométrie en flux à l'aide d'un marquage à l'annexin V-FITC/PI. Des analyses par microscopie électronique à transmission ont été effectuées afin de visualiser l'effet sur la paroi cellulaire et les autres composantes intracellulaires. Les effets du KSL-W ont tous été comparés à ceux de l'amphotéricine B.

**RÉSULTATS** : L'effet antifongique du KSL-W s'amorce dès les premières 30 minutes d'exposition de *C. albicans* et *C. parapsilosis* au KSL-W à des doses de 10 µg/ml. Le KSL-W induit également la nécrose de *C. albicans* à partir de concentrations de 1 µg ml<sup>-1</sup> (49,0%) et 25 µg/ml (97,7%). L'activité du KSL-W sur *C. parapsilosis* est principalement apoptotique (42,2%) après 3 heures d'exposition à 25 µg/ml de KSL-W. Les analyses en microscopie à transmission montrent une atteinte de la membrane de *C. albicans* et de *C. parapsilosis* suivant des traitements de KSL-W à 25 µg/ml.

**CONCLUSIONS** : Nos travaux démontrent une activité antifongique de KSL-W. Cette activité est parfois comparable, parfois non comparable à celle de l'amphotéricine B, (suggérant un mécanisme d'action différent de celui de l'amphotéricine B). Ces travaux suggèrent l'utilisation du KSL-W comme molécule de choix pour le contrôle des infections fongiques à *Candida*.

## Appendix 3

**Titre : Le KSL-W réduit la croissance *Candida albicans* et la formation de biofilm en diminuant l'expression de plusieurs gènes de virulence.**

**Auteurs :** Simon Thériège, Abdelhabib Semlali, Kai P Lung, Abdullah Alamri and Mahmoud Rouabhia

**Présentation :** Poster

**Objectifs :** Le décapeptide  $\alpha$ -hélicoïdal synthétique, le KSL-W (KKVFWVKFK) possède un large spectre affectant plusieurs souches de pathogènes bactériens oraux. Cependant l'effet de ce peptide sur des souches fongiques dont *Candida albicans* reste à démontrer. Le but est d'étudier de l'effet du KSL-W sur les différents facteurs de virulence du *C. albicans*. **Méthodologie :** L'effet de KSL-W a été étudié en analysant la transformation, la prolifération en utilisant la microscopie et le MTT. Ces travaux ont été supportés par des analyses spécifiques à la formation de biofilm (XTT) et à l'activation de certains gènes à l'aide de la technique qRT-PCR. Une analyse de l'activité apoptotique/anti-apoptotique du KSL-W a été réalisée à l'aide d'Annexin V-FITC/IP. Tous les effets étudiés du KSL-W ont été comparés à l'amphotéricine B. **Résultats :** Le KSL-W inhibe la transformation à partir de concentrations de  $5\mu\text{g ml}^{-1}$ . Il s'est montré efficace à inhiber la formation de biofilms à des concentrations de  $50\mu\text{g ml}^{-1}$  et à réduire la viabilité à l'intérieur d'un biofilm mature à des concentrations de  $50\mu\text{g ml}^{-1}$  et est d'efficacité comparable à l'amphotéricine B dans les deux cas. Les analyses ultrastructurales confirment l'efficacité du KSL-W à réduire et à dégrader le biofilm.. L'efficacité du KSL-W passe aussi par la réduction de l'expression de plusieurs gènes dont SAP2, 4, 5, 6, EFG1 et HWP1 impliqués dans la pathogénèse de *C. albicans*. **Conclusion :** Par ses effets importants sur *C. albicans*, le KSL-W pourrait être considéré dans le contrôle de *Candida albicans* ((This study was supported financially by the United States Army Medical Research and Materiel Command (Award number ERMS No. 12304006) and by a grant from the Fonds Émile-Beaulieu, a Université Laval foundation).



# Investigating the effect of an antimicrobial peptide (KSL-W) on gingival fibroblast growth, migration, and defense against microbial infection

Hyun-Jin Park<sup>1</sup>, Mabrouka Salem<sup>1</sup>, Kai P Leung<sup>2</sup>, Mahmoud Rouabhia<sup>1</sup>

<sup>1</sup>Groupe de Recherche en Écologie Buccale, Faculté de Médecine Dentaire, Université Laval, Québec, QC, Canada. <sup>2</sup>Dental and Craniofacial Trauma Research and Tissue Regeneration Directorate, US Army Institute of Surgical Research, Joint Base Fort Sam Houston, TX 78234-6315

## ABSTRACT

**Aim:** The aim of this study was to investigate the interaction between primary human gingival fibroblasts and KSL-W, an antimicrobial peptide, and the effect of this peptide on gingival fibroblast defense *in vitro* against *Streptococcus mutans*.

**Material and Methods:** Primary human gingival fibroblasts were used to study the effect of KSL-W peptide on cell adhesion, growth and the secretion of metalloproteinase (MMP). We also investigated the effect of KSL-W on fibroblast migration by mean of scratch assay. Finally we analyzed the effect of antimicrobial activity of KSL-W on *S. mutans* infected fibroblast cultures

**Results:** The peptide KSL-W promoted fibroblast growth by increasing the S and G2/M cell cycle phases. Peptide KSL-W also regulated the secretion of metalloproteinase (MMP)-1 and -2, through MMP inhibitors such as tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2. Using an *in vitro* wound healing assay, we demonstrated that peptide KSL-W promoted fibroblast migration as compared to non-treated cultures. The addition of KSL-W peptide to *S. mutans* infected fibroblast culture prevents adverse effect of the bacteria through fibroblast growth and IL-8 secretion.

**Conclusion:** These findings therefore show that peptide KSL-W was safe to use with human cells, as it promoted their growth and migration and attenuated *S. mutans* virulence by decreasing its effect on cell viability and IL-8 secretion.

**Significance and Impact:** This study points to the possibility of using KSL-W as antimicrobial peptide, and as a peptide accelerating the wound healing process.

## Acknowledgments:

This study was supported financially by the United States Army Medical Research and Materiel Command (Award number ERMS No. 12304006) and by a grant from the Fonds Émile-Beaulieu.